Viatris (VTRS) 10-Q9 May 242024 Q1 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - € / shares	3 Months Ended
Cover Page - € / shares	Mar. 31, 2024	May 06, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-39695
Entity Registrant Name	VIATRIS INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	83-4364296
Entity Address, Address Line One	1000 Mylan Boulevard
Entity Address, City or Town	Canonsburg
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	15317
City Area Code	724
Local Phone Number	514-1800
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	VTRS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filler Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Common Stock, Par or Stated Value Per Share	€ 0.01
Entity Common Stock, Shares Outstanding		1,190,675,819
Entity Central Index Key	0001792044
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net sales	$ 3,653.5	$ 3,719.1
Total revenues	3,663.4	3,729.1
Cost of sales	2,159.4	2,186.9
Gross profit	1,504	1,542.2
Operating expenses:
Research and development	199.7	182.9
Selling, general and administrative	1,017.5	958.9
Litigation settlements and other contingencies, net	76.8	0.6
Total operating expenses	1,300.1	1,142.4
Earnings from operations	203.9	399.8
Interest expense	138.4	147
Other income, net	(139.1)	(69.9)
Earnings before income taxes	204.6	322.7
Income tax provision	90.7	98
Net earnings	$ 113.9	$ 224.7
Earnings per share attributable to Viatris Inc. shareholders
Basic (in USD per share)	$ 0.10	$ 0.19
Diluted (in USD per share)	$ 0.09	$ 0.19
Weighted average shares outstanding:
Basic (in shares)	1,195.2	1,202.5
Diluted (in shares)	1,209.5	1,205.6
Other Research and Development Expense	$ 6.1	$ 0
Other Revenues
Other revenues	$ 9.9	$ 10

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Comprehensive Loss - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net earnings attributable to Viatris Inc. common shareholders	$ 113.9	$ 224.7
Other comprehensive loss, before tax:
Foreign currency translation adjustment	(342.5)	45.3
Change in unrecognized (loss) gain and prior service cost related to defined benefit plans	(6.2)	1.3
Net unrealized (loss) gain on available-for-sale fixed income securities	(0.3)	0.9
Other comprehensive loss, before tax	(151.2)	(15.9)
Income tax provision (benefit)	42.4	(12.5)
Other comprehensive loss, net of tax	(193.6)	(3.4)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total	(79.7)	221.3
Cash Flow Hedging
Other comprehensive loss, before tax:
Net unrecognized gain (loss) on derivatives	28.7	2.8
Net Investment Hedging
Other comprehensive loss, before tax:
Net unrecognized gain (loss) on derivatives	$ 169.1	$ (66.2)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,014.6	$ 991.9
Accounts receivable, net	3,632	3,700.4
Inventories	3,823.2	3,469.7
Prepaid expenses and other current assets	1,933.3	2,028.1
Assets held for sale	2,520.4	2,786
Total current assets	12,923.5	12,976.1
Property, plant and equipment, net	2,708.2	2,759.6
Intangible assets, net	19,133.7	19,181.1
Goodwill	9,693.5	9,867.1
Deferred income tax benefit	653.2	692.9
Other assets	2,231.6	2,208.7
Total assets	47,343.7	47,685.5
Current liabilities:
Accounts payable	2,196.9	1,938.2
Income taxes payable	148.4	226.8
Current portion of long-term debt and other long-term obligations	1,898.1	1,943.4
Liabilities held for sale	234.8	275.1
Other current liabilities	3,281.7	3,393.9
Total current liabilities	7,759.9	7,777.4
Long-term debt	16,072.5	16,188.1
Deferred income tax liability	1,671.9	1,735.7
Other long-term obligations	1,825.1	1,516.9
Total liabilities	27,329.4	27,218.1
Viatris Inc. shareholders’ equity
Common stock: $0.01 par value, 3,000,000,000 shares authorized; shares issued: 1,230,891,074 and 1,221,994,491 as of March 31, 2024 and December 31, 2023	12.3	12.2
Additional paid-in capital	18,839.8	18,814.7
Retained earnings	4,607.5	4,639.7
Accumulated other comprehensive loss	(2,941)	(2,747.4)
Total Viatris Inc. equity, before treasury stock	20,518.6	20,719.2
Less: Treasury stock — at cost	504.3	251.8
Total equity	20,014.3	20,467.4
Total liabilities and equity	$ 47,343.7	$ 47,685.5

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2023 shares
Ordinary shares, shares authorized	3,000,000,000
Treasury stock, shares	21,239,521

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Stock, Value	$ 0
Treasury Stock, Common, Shares	0
Balance at Dec. 31, 2022	$ 21,072,300	$ 12,100	$ 18,645,800	$ 5,175,600	$ (2,761,200)
Balance (in shares) at Dec. 31, 2022		1,213,793,231
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	224,700
Other comprehensive loss, net of tax	(3,400)				(3,400)
Issuance of restricted stock, net of shares withheld (in shares)		6,350,585
Issuance of restricted stock and stock options exercised, net	3,700	$ 100	3,600
Taxes related to the net share settlement of equity awards	(19,400)		(19,400)
Share-based compensation expense	42,600		42,600
Common stock repurchase	(251,800)					$ (251,800)
Payments for Repurchase of Common Stock	$ 250,000
Stock Issued During Period, Shares, New Issues		80,388
Treasury Stock, Shares, Acquired	21,200,000					21,239,521
Stock Issued During Period, Value, New Issues	$ 900		900
Cash dividends declared, $0.12 per common share	(147,800)			(147,800)
Other Additional Capital	6,100
Balance at Mar. 31, 2023	20,927,900	$ 12,200	18,679,600	5,252,500	(2,764,600)
Balance (in shares) at Mar. 31, 2023		1,220,224,204
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Stock, Value	$ (251,800)
Treasury Stock, Common, Shares	21,239,521
Treasury Stock, Value	$ (251,800)
Treasury Stock, Common, Shares	21,239,521
Balance at Dec. 31, 2023	$ 20,467,400	$ 12,200	18,814,700	4,639,700	(2,747,400)
Balance (in shares) at Dec. 31, 2023		1,221,994,491
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	113,900
Other comprehensive loss, net of tax	(193,600)				(193,600)
Issuance of restricted stock, net of shares withheld (in shares)		8,842,107
Issuance of restricted stock and stock options exercised, net	6,700	$ 100	6,600
Taxes related to the net share settlement of equity awards	(28,800)		(28,800)
Share-based compensation expense	46,700		46,700
Common stock repurchase	(252,500)					$ (252,500)
Payments for Repurchase of Common Stock	$ 250,000
Stock Issued During Period, Shares, New Issues		54,476
Treasury Stock, Shares, Acquired	19,200,000					19,244,142
Stock Issued During Period, Value, New Issues	$ 600		600
Cash dividends declared, $0.12 per common share	(146,100)			(146,100)
Balance at Mar. 31, 2024	20,014,300	$ 12,300	$ 18,839,800	$ 4,607,500	$ (2,941,000)
Balance (in shares) at Mar. 31, 2024		1,230,891,074
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Stock, Value	$ (504,300)
Treasury Stock, Common, Shares	40,483,663

Condensed Consolidated Statem_3

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net earnings attributable to Viatris Inc. common shareholders	$ 113.9	$ 224.7
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	691	730
Share-based compensation expense	46.7	42.6
Deferred income tax benefit	(51.9)	(26.7)
Gain on disposal of business	(70.4)	0
Acquired IPR&D	(5.2)	0
Other non-cash items	(3)	29.6
Litigation settlements and other contingencies, net	80.3	2.4
Changes in operating assets and liabilities:
Accounts receivable	9.8	215
Inventories	(370.4)	(151.1)
Accounts payable	287.9	183.4
Income taxes	(2.3)	(53.9)
Other operating assets and liabilities, net	(111.8)	(224.8)
Net cash provided by operating activities	614.6	971.2
Cash flows from investing activities:
Cash paid for acquisitions, net of cash acquired	(350)	(667.7)
Capital expenditures	(49.8)	(47.8)
Purchase of marketable securities	(7.7)	(9)
Proceeds from the sale of marketable securities	7.7	9
Payments for product rights and other, net	(1)	(34.7)
Refund of IPR&D	5.2	0
Proceeds from sale of assets and subsidiaries	240.6	0
Proceeds from the sale of property, plant and equipment	0.7	0.7
Net cash used in investing activities	(154.3)	(749.5)
Cash flows from financing activities:
Payments of long-term debt	0	(750.1)
Purchase of common stock	(250)	(250)
Change in short-term borrowings, net	0	204.6
Taxes paid related to net share settlement of equity awards	(28.7)	(30)
Contingent consideration payments	(10.9)	(8.4)
Cash dividends paid	(142.8)	(143.8)
Non-contingent payments for product rights	0	(9.7)
Issuance of common stock	0.6	0.9
Other items, net	6.2	11.8
Net cash used in financing activities	(425.6)	(974.7)
Effect on cash of changes in exchange rates	(12.4)	1.2
Net increase (decrease) in cash, cash equivalents and restricted cash	22.3	(751.8)
Cash, cash equivalents and restricted cash — beginning of period	993.6	1,262.5
Cash, cash equivalents and restricted cash — end of period	$ 1,015.9	$ 510.7

Collaboration and Licensing Agr

Collaboration and Licensing Agreements	3 Months Ended
Collaboration and Licensing Agreements	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and Licensing Agreements	Licensing and Other Partner Agreements We periodically enter into licensing and other partner agreements with other pharmaceutical companies for the development, manufacture, marketing and/or sale of pharmaceutical products. Our significant licensing and other partner agreements are primarily focused on the development, manufacturing, supply and commercialization of multiple complex products. Under these agreements, we have future potential milestone payments and co-development expenses payable to third parties as part of our licensing, development and co-development programs. Payments under these agreements generally become due and are payable upon the satisfaction or achievement of certain developmental, regulatory or commercial milestones or as development expenses are incurred on defined projects. Milestone payment obligations are uncertain, including the prediction of timing and the occurrence of events triggering a future obligation and are not reflected as liabilities in the condensed consolidated balance sheets, except for obligations reflected as acquisition related contingent consideration, including those related to the Idorsia Transaction. Refer to Note 11 Financial Instruments and Risk Management for further discussion of contingent consideration. Our potential maximum development milestones not accrued for at March 31, 2024 totaled approximately $409 million . We estimate that the amounts that may be paid through the end of 2024 to be approximately $18 million. These agreements may also include potential sales-based milestones and call for us to pay a percentage of amounts earned from the sale of the product as a royalty or a profit share. The amounts disclosed do not include sales-based milestones or royalty or profit share obligations on future sales of product as the timing and amount of future sales levels and costs to produce products subject to these obligations is not reasonably estimable. These sales-based milestones or royalty or profit share obligations may be significant depending upon the level of commercial sales for each product. Mapi In 2018, the Company entered into an exclusive license and commercialization agreement with Mapi for the development and commercialization on a world-wide basis of GA Depot. Under the terms of the license and commercialization agreement, as of March 31, 2024, Mapi is eligible to receive regulatory approval and commercial launch milestone payments of up to $90.0 million. Additionally, upon commercial launch of GA Depot, Mapi is eligible to receive potential contingent payments, such as tiered royalties and tiered sales-based milestones. In December 2023, the Company entered into a letter agreement, as amended, with Mapi for the development and commercialization of certain additional products, which is subject to finalization pending the execution of a definitive agreement, which is expected in the first half of 2024. The Company made an initial upfront payment of $75.0 million which was accounted for as Acquired IPR&D expense in the consolidated statements of operations during the fourth quarter of 2023. During the first quarter of 2024, the Company was informed that Mapi received a Complete Response Letter (“CRL”) regarding the NDA for GA Depot 40 mg from the FDA. The Companies are reviewing the content of the CRL and will be determining the appropriate next steps. The Company holds investments in preferred shares of Mapi that are accounted for at cost, less impairment, if any, adjusted for observable price changes, in accordance with ASC 321, Investments – Equity Securities . During the second quarter of 2023, the Company made an additional investment of $30.0 million in preferred shares of Mapi. The preferred shares are convertible on a one-to-one basis into Mapi ordinary shares at Viatris’ option. The Company recognized a gain of $45.6 million during the second quarter of 2023 as a result of remeasuring our pre-existing equity interest in Mapi, which was recorded as a component of Other Income, Net in the condensed consolidated statements of operations. The Company has determined that Mapi represents a variable interest entity (“VIE”), but has concluded that Viatris is not the primary beneficiary of Mapi as we do not have the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance. Accordingly, we have not consolidated Mapi’s results of operations and financial position into our condensed consolidated financial statements. As of each of March 31, 2024 and December 31, 2023, our condensed consolidated balance sheets included, within Other Assets , $132.1 million related to our equity investments in Mapi, which included cumulative unrealized gains of $62.1 million, and within Prepaid Expenses and Other Current Assets , $52.5 million related to advances, including for initial orders of commercial launch supply of GA Depot under our supply agreement with Mapi. Our maximum exposure to loss as a result of our involvement with Mapi is limited to the carrying value of the investments and advances. There have been no other significant changes to our licensing and other partner agreements as disclosed in our 2023 Form 10-K.

General

General	3 Months Ended
General	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	General The accompanying unaudited condensed consolidated financial statements (“interim financial statements”) of Viatris Inc. and subsidiaries were prepared in accordance with U.S. GAAP and the rules and regulations of the SEC for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in audited financial statements were condensed or omitted. The interim financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the interim results of operations, comprehensive loss, financial position, equity and cash flows for the periods presented. These interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto in Viatris’ 2023 Form 10-K. The December 31, 2023 condensed consolidated balance sheet was derived from audited financial statements. The interim results of operations, comprehensive loss and cash flows for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or any other future period.

Revenue Recognition and Account

Revenue Recognition and Accounts Receivable	3 Months Ended
Revenue Recognition and Accounts Receivable	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue Recognition and Accounts Receivable	Revenue Recognition and Accounts Receivable The Company recognizes revenues in accordance with ASC 606, Revenue from Contracts with Customers . Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the condensed consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Our net sales may be impacted by wholesaler and distributor inventory levels of our products, which can fluctuate throughout the year due to the seasonality of certain products, pricing, the timing of product demand, purchasing decisions and other factors. Such fluctuations may impact the comparability of our net sales between periods. Consideration received from licenses of intellectual property is recorded as other revenues. Royalty or profit share amounts, which are based on sales of licensed products or technology, are recorded when the customer’s subsequent sales or usages occur. Such consideration is included in other revenues in the condensed consolidated statements of operations. The following table presents the Company’s net sales by product category for each of our reportable segments for the three months ended March 31, 2024 and 2023, respectively: (In millions) Three Months Ended March 31, 2024 Product Category Developed Markets Greater China JANZ Emerging Markets Total Brands $ 1,178.8 $ 541.8 $ 184.1 $ 404.4 $ 2,309.1 Generics 986.6 2.1 133.7 222.0 1,344.4 Total Viatris $ 2,165.4 $ 543.9 $ 317.8 $ 626.4 $ 3,653.5 (In millions) Three Months Ended March 31, 2023 Product Category Developed Markets Greater China JANZ Emerging Markets Total Brands $ 1,232.0 $ 562.4 $ 190.3 $ 435.6 $ 2,420.3 Generics 938.4 2.2 151.9 206.3 1,298.8 Total Viatris $ 2,170.4 $ 564.6 $ 342.2 $ 641.9 $ 3,719.1 ____________ (a) Amounts for the three months ended March 31, 2024 include the impact of foreign currency translations compared to the prior year period. (b) Complex Gx , which were previously presented as a separate line item in the prior year period, are now included within Generics. Reclassifications were made to prior periods to conform to the current period presentation. The following table presents net sales on a consolidated basis for select key products for the three months ended March 31, 2024 and 2023, respectively: Three months ended March 31, (In millions) 2024 2023 Select Key Global Products Lipitor ® $ 388.9 $ 417.9 Norvasc ® 176.3 202.7 Lyrica ® 114.2 144.3 Viagra ® 100.7 115.0 EpiPen® Auto-Injectors 80.2 95.8 Creon ® 75.0 72.7 Celebrex ® 72.2 88.8 Effexor ® 59.4 64.6 Zoloft ® 58.0 56.5 Xalabrands 42.5 46.7 Select Key Segment Products Yupelri ® $ 55.2 $ 47.0 Dymista ® 48.2 53.2 Xanax ® 34.5 39.7 Amitiza ® 33.0 36.6 ____________ (a) The Company does not disclose net sales for any products considered competitively sensitive. (b) Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches. (c) Amounts for the three months ended March 31, 2024 include the impact of foreign currency translations compared to the prior year period. (d) Refer to intellectual property matters included in Note 17 Litigation for additional information regarding Yupelri® and Amitiza®. Variable Consideration and Accounts Receivable The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three months ended March 31, 2024 and 2023, respectively: Three Months Ended March 31, (In millions) 2024 2023 Gross sales $ 6,174.6 $ 6,273.0 Gross to net adjustments: Chargebacks (1,244.2) (1,350.7) Rebates, promotional programs and other sales allowances (1,048.3) (992.2) Returns (60.3) (50.4) Governmental rebate programs (168.3) (160.6) Total gross to net adjustments $ (2,521.1) $ (2,553.9) Net sales $ 3,653.5 $ 3,719.1 No significant revisions were made to the methodology used in determining these provisions or the nature of the provisions during the three months ended March 31, 2024. Such allowances were comprised of the following at March 31, 2024 and December 31, 2023, respectively: (In millions) March 31, December 31, Accounts receivable, net $ 1,482.5 $ 1,483.6 Other current liabilities 1,008.8 996.3 Total $ 2,491.3 $ 2,479.9 Accounts receivable, net was comprised of the following at March 31, 2024 and December 31, 2023, respectively: (In millions) March 31, December 31, Trade receivables, net $ 2,790.0 $ 2,823.8 Other receivables 842.0 876.6 Accounts receivable, net $ 3,632.0 $ 3,700.4 Accounts Receivable Factoring Arrangements

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
Recent Accounting Pronouncements	Mar. 31, 2024
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	Recent Accounting Pronouncements Accounting Standards and Disclosure Rules Issued Not Yet Adopted In March 2024, the SEC adopted final rules under SEC Release No. 34-99678 and No. 33-11275, “The Enhancement and Standardization of Climate-Related Disclosures for Investors” (the “Final Rules”), which will require registrants to provide certain climate-related information in their registration statements and annual reports. The Final Rules require, among other things, disclosure in the notes to the audited financial statements of the effects of severe weather events and other natural conditions, subject to certain thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates in certain circumstances. The Final Rules will also require disclosure outside of the financial statements of material scope 1 and scope 2 greenhouse gas emissions, among other climate-related disclosures. The disclosure requirements of the Final Rules will begin phasing in for the Company for fiscal year 2025. In April 2024, the SEC stayed the effectiveness of the Final Rules. The Company is currently assessing the impact of the new rules on its consolidated financial statements and disclosures. There were no other significant changes in new accounting standards from those disclosed in Viatris’ 2023 Form 10-K. Refer to Viatris’ 2023 Form 10-K for additional information.

Acquisitions and Other Transact

Acquisitions and Other Transactions	3 Months Ended
Acquisitions and Other Transactions	Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]
Acquisitions and Other Transactions	Acquisitions and Other Transactions Idorsia On March 15, 2024, the Company acquired the development programs and certain personnel related to selatogrel and cenerimod from Idorsia in exchange for an upfront payment to Idorsia of $350 million, potential milestone payments (including $300 million payable upon the achievement of certain development and regulatory milestones, and $2.1 billion payable upon the achievement of certain tiered sales milestones), as well as potential contingent tiered sales royalties. Viatris and Idorsia are both contributing to the development costs for both programs. Viatris has worldwide commercialization rights for both selatogrel and cenerimod (excluding, for cenerimod only, Japan, South Korea and certain countries in the Asia-Pacific region). A joint development committee is overseeing the development of the ongoing Phase 3 programs through regulatory approval. The agreements also provide Viatris a right of first refusal and a right of first negotiation for certain other assets in Idorsia’s pipeline. The transaction expands our portfolio of innovative assets by adding two Phase 3 assets and combines our financial strength and worldwide operational infrastructure with Idorsia’s proven, highly-productive drug development team and innovation engine. In accordance with U.S. GAAP, the transaction has been accounted for as a business combination under the acquisition method of accounting. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. During the three months ended March 31, 2024, the Company incurred acquisition-related costs of approximately $0.3 million, which were recorded primarily in SG&A in the condensed consolidated statements of operations. The U.S. GAAP purchase price allocated to the transaction was $695 million, which consisted of $350 million of cash consideration paid and estimated contingent consideration at the date of acquisition valued at approximately $345 million. The fair value of the contingent consideration was valued using a Monte Carlo simulation model using Level 3 inputs. The fair value is sensitive to changes in the forecasts of operating metrics, probability of success, and discount rates. Refer to Note 11, Financial Instruments and Risk Management , for additional information. The preliminary allocation of the purchase price to the assets acquired and liabilities assumed is as follows: (In millions) Current assets $ 2.1 IPR&D 675.0 Goodwill 19.5 Total assets acquired $ 696.6 Current liabilities 1.6 Net assets acquired $ 695.0 The preliminary fair value estimates for the assets acquired and liabilities assumed were based upon preliminary calculations, valuations and assumptions that are subject to change as the Company obtains additional information during the measurement period (up to one year from the acquisition date). The primary areas subject to change relate to the finalization of the valuation of IPR&D, contingent consideration, and income taxes. The amount allocated to IPR&D represents an estimate of the fair value of purchased in-process technology for research projects that, as of the closing date of the acquisition, had not reached technological feasibility and had no alternative future use. The fair value of IPR&D of $675 million was based on the excess earnings method, which utilizes forecasts of expected cash inflows (including estimates for ongoing costs) and other contributory charges. A discount rate of 20% was utilized to discount net cash inflows to present values. IPR&D is accounted for as an indefinite-lived intangible asset and will be subject to impairment testing until completion or abandonment of the projects. Upon successful completion and launch of each product, the Company will make a determination of the estimated useful life of the individual asset. Viatris and Idorsia will both contribute to the development costs for both programs, which are expected to be incurred through 2026. There are risks and uncertainties associated with the timely and successful completion of the projects included in IPR&D, and no assurances can be given that the underlying assumptions used to estimate the fair value of IPR&D will not change or the timely completion of each project to commercial success will occur. The goodwill of $19.5 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is currently expected to be deductible for income tax purposes. The acquisition did not have a material impact on the Company’s results of operations since the acquisition date or on a pro forma basis for the three months ended March 31, 2024 and 2023.

Divestitures

Divestitures	3 Months Ended
Divestitures	Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Divestitures	Divestitures On October 1, 2023, the Company announced it received an offer for the divestiture of its OTC Business, and entered into definitive agreements to divest its women’s healthcare business and, separately, in another transaction, its rights to two women’s healthcare products in certain countries, its API business in India and commercialization rights in the Upjohn Distributor Markets. The OTC, API and women’s healthcare businesses are deemed businesses for U.S. GAAP accounting purposes. As such, the assets and liabilities include an allocation of goodwill. The sale of the rights to two women’s healthcare products in certain countries was accounted for as an asset sale. In conjunction with these transactions, Viatris and the respective buyers have entered or will enter into various agreements to provide a framework for our relationship with the respective buyers after the closing of the divestitures, including TSAs, manufacturing and supply agreements, and distribution agreements, as necessary. During the three months ended March 31, 2024 and 2023, the Company recognized TSA income related to the divestitures of approximately $13.4 million and $45.7 million, respectively, as a component of Other Income, Net . Women’s Healthcare In the third quarter of 2023, Viatris executed an agreement to divest its women’s healthcare business, primarily related to oral and injectable contraceptives, to Insud Pharma, S. L., a leading Spanish multinational pharmaceutical company. The divestiture of the women’s healthcare business is primarily related to our oral and injectable contraceptives and does not include all of our women’s healthcare related products; as an example, our Xulane® product in the U.S. is excluded. The transaction includes two manufacturing facilities in India. Assets and liabilities associated with the women’s healthcare business to be divested were classified as held for sale in the consolidated balance sheet as of December 31, 2023. The transaction closed in March 2024 and upon closing, the Company recognized a pre-tax gain on sale of approximately $80.8 million for the difference between the consideration received and the carrying value of the assets transferred (including an allocation of goodwill). The gain was recorded as a component of Other Income, Net in the condensed consolidated statement of operations during the three months ended March 31, 2024. In the third quarter of 2023, Viatris also entered into a separate agreement to divest its rights to women’s healthcare products Duphaston® and Femoston® in certain countries to Theramex HQ UK Limited, a leading global specialty pharmaceutical company dedicated to women’s health. The transaction (other than in the U.K., which remains subject to regulatory approval) closed in December 2023, and upon closing, the Company recognized a pre-tax gain on sale of approximately $156.2 million in that quarter for the difference between the consideration received and the carrying value of the assets transferred. The gain was recorded as a component of SG&A expense in the consolidated statement of operations during the year ended December 31, 2023. OTC On October 1, 2023, Viatris received an offer from Cooper Consumer Health SAS, a leading European OTC drug manufacturer and distributor, for Viatris to divest its OTC Business, including two manufacturing sites located in Merignac, France, and Confienza, Italy, and an R&D site in Monza, Italy. In January 2024, we exercised our option to accept the offer in the OTC Transaction and entered into a definitive transaction agreement with respect to such OTC Transaction. The Company will retain rights for Viagra®, Dymista® (which, in certain limited markets, are sold as OTC products) and select OTC products in certain markets. The Company currently expects the OTC Transaction to close by mid-year 2024. The transaction remains subject to regulatory approvals, receipt of required consents and other closing conditions. The OTC Business to be divested met the criteria to be classified as held for sale on October 1, 2023. As such, the related assets and liabilities were classified as held for sale in the condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023. Upon classification as held for sale in the fourth quarter of 2023, we recognized a total charge of approximately $734.7 million, which was comprised of a goodwill impairment charge of approximately $580.1 million (recorded as a component of SG&A expense), and a charge of approximately $154.7 million to write down the disposal group to fair value, less cost to sell (recorded as a component of Other Income, Net) in the consolidated statement of operations. API On October 1, 2023, Viatris executed an agreement to divest its API business in India to Matrix Pharma Private Limited, an affiliate of IQuest Enterprises Private Limited, a privately held pharmaceutical company based in India. The transaction includes three manufacturing sites and a R&D lab in Hyderabad, three manufacturing sites in Vizag and third-party API sales. Viatris will retain some selective R&D capabilities in API. The API business in India met the criteria to be classified as held for sale on October 1, 2023 and the related assets and liabilities were reclassified as held for sale in the consolidated balance sheet as of December 31, 2023. The transaction is expected to close imminently. The Company recognized a pre-tax charge of approximately $10.4 million to write down the disposal group to fair value, less cost to sell (recorded as a component of Other Income, Net) in the condensed consolidated statement of operations. Upjohn Distributor Markets In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $374.2 million in 2022, which was comprised of a goodwill impairment charge of $117.0 million, other charges, principally inventory write-offs, of $84.3 million and a charge of approximately $172.9 million to write down the disposal group to fair value, less cost to sell. During the year ended December 31, 2023, the Company recorded additional charges totaling $136.4 million, primarily consisting of losses on the disposals of $85.2 million, which were recorded as a component of Other Income, Net . The additional charges include inventory reserves of $9.2 million and an intangible asset charge of $32.0 million to write down the disposal group to fair value, less cost to sell, in each case during the three months ended March 31, 2023. The divestitures of the commercialization rights in certain of the Upjohn Distributor Markets closed during 2023 and the remaining transactions are expected to be completed during 2024. If the remaining transactions are not completed, the distribution arrangements will expire in accordance with our agreement with Pfizer and the Company will wind down operations in these markets, which may result in additional asset write-offs and other costs being incurred. Biocon Biologics Transaction On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $3 billion in consideration in the form of a $2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $1 billion of CCPS representing a stake of approximately 12.9% (on a fully diluted basis) in Biocon Biologics. During the three months ended March 31, 2024 and 2023, the Company recorded a gain of $46.9 million and a loss of $2.6 million, respectively, as a component of Other Income, Net , as a result of remeasuring the CCPS in Biocon Biologics to fair value. The Company’s CCPS in Biocon Biologics are classified as equity securities and are included in Other Assets in the condensed consolidated balance sheets. The fair value is reassessed quarterly. Refer to Note 11 Financial Instruments and Risk Management for further discussion. Viatris also is entitled to $335 million of additional cash payments in 2024. In addition, Viatris and Biocon Biologics have agreed to a closing working capital target of $250 million, of which $220 million was paid during 2023. Refer to Note 8 Balance Sheet Components for additional information on assets and liabilities related to Biocon Biologics. At the time of closing of the Biocon Biologics Transaction, Viatris and Biocon Biologics also entered an agreement pursuant to which Viatris was providing commercialization and certain other transition services on behalf of Biocon Biologics, including billings, collections, and the remittance of rebates, to ensure business continuity for patients, customers and colleagues. Biocon Biologics had substantially exited all transition services with Viatris as of December 31, 2023. Assets and Liabilities Held for Sale Assets and liabilities held for sale consisted of the following: (In millions) March 31, 2024 December 31, 2023 Assets held for sale Accounts receivable, net $ 57.6 $ 112.1 Inventories 408.9 422.4 Prepaid expenses and other current assets 5.0 7.5 Property, plant and equipment, net 239.0 262.2 Intangible assets, net 1,846.5 1,946.0 Goodwill 119.1 188.0 Other assets 3.3 5.1 Valuation allowance on assets held for sale (159.0) (157.3) Total assets held for sale $ 2,520.4 $ 2,786.0 Liabilities held for sale Accounts payable $ 126.2 $ 137.4 Other current liabilities 34.0 35.3 Deferred income tax liability 48.8 77.2 Other long-term obligations 25.8 25.2 Total liabilities held for sale $ 234.8 $ 275.1

Share-Based Incentive Plan

Share-Based Incentive Plan	3 Months Ended
Share-Based Incentive Plan	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Incentive Plan	Share-Based Incentive Plan Prior to the Distribution, Viatris adopted and Pfizer, in the capacity as Viatris’ sole stockholder at such time, approved the 2020 Incentive Plan (the Viatris Inc. 2020 Stock Incentive Plan ) which became effective as of the Distribution. In connection with the Combination, as of November 16, 2020, the Company assumed the 2003 LTIP ( Mylan N.V. Amended and Restated 2003 Long-Term Incentive Plan ), which had previously been approved by Mylan shareholders. The 2020 Incentive Plan includes 72,500,000 shares of Viatris’ common stock authorized for grant pursuant to the 2020 Incentive Plan, which may include dividend payments payable in common stock on unvested shares granted under awards. No shares remain available for issuance under the 2003 LTIP, however, certain awards remain outstanding under the plan. Under the 2020 Incentive Plan, shares are reserved for issuance to key employees, consultants, independent contractors and non-employee directors of the Company through a variety of incentive awards, including: stock options, SARs, restricted stock and units, PSUs, other stock-based awards and short-term cash awards. Stock option awards are granted with an exercise price equal to the fair market value of the shares underlying the stock options at the date of the grant, generally become exercisable over periods ranging from three The following table summarizes stock awards (stock options and SARs) activity: Number of Shares Under Stock Awards Weighted Average Exercise Price per Share Outstanding at December 31, 2023 4,159,333 $ 37.41 Exercised (18,012) 9.02 Forfeited (417,916) $ 53.13 Outstanding at March 31, 2024 3,723,405 $ 35.79 Vested and expected to vest at March 31, 2024 3,707,337 $ 35.90 Exercisable at March 31, 2024 3,597,026 $ 36.72 As of March 31, 2024, stock awards outstanding, stock awards vested and expected to vest, and stock awards exercisable had average remaining contractual terms of 3.8 years, 3.7 years and 3.6 years, respectively. Also, at March 31, 2024, stock awards outstanding, stock awards vested and expected to vest, and stock awards exercisable had aggregate intrinsic values of $0.8 million, $0.8 million, and $0.4 million, respectively. A rollforward of the changes in the Company’s nonvested Restricted Stock Awards (restricted stock and restricted stock unit awards, including PSUs) from December 31, 2023 to March 31, 2024 is presented below: Number of Restricted Stock Awards Weighted Average Grant-Date Fair Value Per Share Nonvested at December 31, 2023 31,096,783 $ 11.20 Granted 13,326,359 12.38 Released (10,336,912) 11.92 Forfeited (1,305,912) 11.00 Nonvested at March 31, 2024 32,780,318 $ 11.46 As of March 31, 2024, the Company had $287.6 million of total unrecognized compensation expense, net of estimated forfeitures, related to all of its stock-based awards, which we expect to recognize over the remaining weighted average vesting period of 1.8 years. The total intrinsic value of Restricted Stock Awards released and stock options exercised during the three months ended March 31, 2024 and 2023 was $129.0 million and $100.8 million, respectively.

Pensions and Other Postretireme

Pensions and Other Postretirement Benefits	3 Months Ended
Pensions and Other Postretirement Benefits	Mar. 31, 2024
Retirement Benefits [Abstract]
Pension and Other Postretirement Benefits Disclosure	Pensions and Other Postretirement Benefits Defined Benefit Plans The Company sponsors various defined benefit pension plans in several countries. Benefits provided generally depend on length of service, pay grade and remuneration levels. Employees in the U.S., Puerto Rico and certain international locations are also provided retirement benefits through defined contribution plans. The Company also sponsors other postretirement benefit plans including plans that provide for postretirement supplemental medical coverage. Benefits from these plans are provided to employees and their spouses and dependents who meet various minimum age and service requirements. In addition, the Company sponsors other plans that provide for life insurance benefits and postretirement medical coverage for certain officers and management employees. Net Periodic Benefit Cost Components of net periodic benefit cost for the three months ended March 31, 2024 and 2023 were as follows: Pension and Other Postretirement Benefits Three Months Ended March 31, (In millions) 2024 2023 Service cost $ 7.9 $ 7.1 Interest cost 16.6 18.3 Expected return on plan assets (16.9) (16.4) Amortization of prior service costs 0.5 — Recognized net actuarial gains (4.3) (5.0) Net periodic benefit cost $ 3.8 $ 4.0 The Company is making the minimum mandatory contributions to its defined benefit pension plans in the U.S. and Puerto Rico for the 2024 plan year. The Company expects to make total benefit payments of approximately $114.4 million from pension and other postretirement benefit plans in 2024. The Company anticipates making contributions to pension and other postretirement benefit plans of approximately $61.3 million in 2024.

Balance Sheet Components

Balance Sheet Components	3 Months Ended
Balance Sheet Components	Mar. 31, 2024
Balance Sheet Components [Abstract]
Balance Sheet Components	Balance Sheet Components Selected balance sheet components consist of the following: Cash and restricted cash (In millions) March 31, December 31, March 31, 2023 Cash and cash equivalents $ 1,014.6 $ 991.9 $ 506.6 Restricted cash, included in prepaid expenses and other current assets 1.3 1.7 4.1 Cash, cash equivalents and restricted cash $ 1,015.9 $ 993.6 $ 510.7 Inventories (In millions) March 31, December 31, Raw materials $ 686.7 $ 731.7 Work in process 1,097.5 602.1 Finished goods 2,039.0 2,135.9 Inventories $ 3,823.2 $ 3,469.7 Prepaid expenses and other current assets (In millions) March 31, December 31, 2023 Prepaid expenses $ 178.9 $ 155.9 Deferred consideration due from Biocon Biologics 328.3 321.2 Available-for-sale fixed income securities 38.7 37.0 Fair value of financial instruments 73.3 106.2 Equity securities 52.1 49.3 Deferred charge for taxes on intercompany profit 701.8 747.3 Income tax receivable 310.7 340.2 Other current assets 249.5 271.0 Prepaid expenses and other current assets $ 1,933.3 $ 2,028.1 Prepaid expenses consist primarily of prepaid rent, insurance and other individually insignificant items. Property, plant and equipment, net (In millions) March 31, December 31, 2023 Machinery and equipment $ 2,745.8 $ 2,774.5 Buildings and improvements 1,438.8 1,444.4 Construction in progress 406.5 431.2 Land and improvements 114.6 120.2 Gross property, plant and equipment 4,705.7 4,770.3 Accumulated depreciation 1,997.5 2,010.7 Property, plant and equipment, net $ 2,708.2 $ 2,759.6 Other assets (In millions) March 31, December 31, 2023 Non-marketable equity investments $ 165.7 $ 165.7 CCPS in Biocon Biologics 1,023.2 976.3 Operating lease right-of-use assets 242.1 245.6 Other long-term assets 800.6 821.1 Other assets $ 2,231.6 $ 2,208.7 Accounts payable (In millions) March 31, December 31, 2023 Trade accounts payable $ 1,584.0 $ 1,381.4 Other payables 612.9 556.8 Accounts payable $ 2,196.9 $ 1,938.2 Other current liabilities (In millions) March 31, December 31, 2023 Accrued sales allowances $ 1,008.8 $ 996.3 Legal and professional accruals, including litigation accruals 321.6 244.0 Payroll and employee benefit liabilities 598.2 844.5 Contingent consideration (1) 105.2 76.1 Accrued restructuring 29.9 36.4 Accrued interest 204.7 66.8 Fair value of financial instruments 70.1 124.6 Operating lease liability 91.8 83.0 Other 851.4 922.2 Other current liabilities $ 3,281.7 $ 3,393.9 Other long-term obligations (In millions) March 31, December 31, 2023 Employee benefit liabilities $ 495.1 $ 504.3 Contingent consideration (2) 464.7 139.0 Tax related items, including contingencies 406.3 399.3 Operating lease liability 156.2 165.4 Accrued restructuring 57.9 59.2 Other 244.9 249.7 Other long-term obligations $ 1,825.1 $ 1,516.9

Earnings (Loss) per Ordinary Sh

Earnings (Loss) per Ordinary Share	3 Months Ended
Earnings (Loss) per Ordinary Share	Mar. 31, 2024
Earnings Per Share [Abstract]
Earnings (Loss) per Ordinary Share	Earnings per Share Basic earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period. Diluted earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive. Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows: Three Months Ended March 31, (In millions, except per share amounts) 2024 2023 Basic earnings attributable to Viatris Inc. common shareholders (numerator): Net earnings attributable to Viatris Inc. common shareholders $ 113.9 $ 224.7 Shares (denominator): Weighted average shares outstanding 1,195.2 1,202.5 Basic earnings per share attributable to Viatris Inc. shareholders $ 0.10 $ 0.19 Diluted earnings attributable to Viatris Inc. common shareholders (numerator): Net earnings attributable to Viatris Inc. common shareholders $ 113.9 $ 224.7 Shares (denominator): Weighted average shares outstanding 1,195.2 1,202.5 Share-based awards 14.3 3.1 Total dilutive shares outstanding 1,209.5 1,205.6 Diluted earnings per share attributable to Viatris Inc. shareholders $ 0.09 $ 0.19 Additional stock awards and Restricted Stock Awards were outstanding during the three months ended March 31, 2024 and 2023, but were not included in the computation of diluted earnings per share for each respective period because the effect would be anti-dilutive. Excluded shares at March 31, 2024 also include certain share-based compensation awards and restricted shares whose performance conditions had not been fully met. Such excluded shares and anti-dilutive awards represented 7.9 million shares and 13.9 million shares for the three months ended March 31, 2024 and 2023, respectively. The Company paid a quarterly dividend of $0.12 per share on the Company’s issued and outstanding common stock on March 18, 2024. On May 6, 2024, the Company’s Board of Directors declared a quarterly cash dividend of $0.12 per share on the Company’s issued and outstanding common stock, which will be payable on June 14, 2024 to shareholders of record as of the close of business on May 24, 2024. The declaration and payment of future dividends to holders of the Company’s common stock will be at the discretion of the Board of Directors, and will depend upon factors, including but not limited to, the Company’s financial condition, earnings, capital requirements of its businesses, legal requirements, regulatory constraints, industry practice, and other factors that the Board of Directors deems relevant.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
Goodwill and Intangible Assets	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The changes in the carrying amount of goodwill for the three months ended March 31, 2024 are as follows: (In millions) Developed Markets (1) Greater China JANZ (2) Emerging Markets (3) Total Balance at December 31, 2023: 7,107.4 932.8 645.7 1,181.2 9,867.1 Acquisitions 19.5 — — — 19.5 Foreign currency translation (153.5) (7.5) (24.6) (7.5) (193.1) Balance at March 31, 2024: $ 6,973.4 $ 925.3 $ 621.1 $ 1,173.7 $ 9,693.5 ____________ (1) Balances as of March 31, 2024 and December 31, 2023 include an accumulated impairment loss of $929.0 million. (2) Balances as of March 31, 2024 and December 31, 2023 include an accumulated impairment loss of $30.0 million. (3) Balances as of March 31, 2024 and December 31, 2023 include an accumulated impairment loss of $124.0 million. Intangible Assets, Net Intangible assets consist of the following components at March 31, 2024 and December 31, 2023: (In millions) Weighted Average Life (Years) Original Cost Accumulated Amortization Net Book Value March 31, 2024 Product rights, licenses and other (1) 13 $ 33,830.4 $ 15,690.8 $ 18,139.6 In-process research and development 994.1 — 994.1 $ 34,824.5 $ 15,690.8 $ 19,133.7 December 31, 2023 Product rights, licenses and other (1) 13 $ 34,178.1 $ 15,316.4 $ 18,861.7 In-process research and development 319.4 — 319.4 $ 34,497.5 $ 15,316.4 $ 19,181.1 ____________ (1) Represents amortizable intangible assets. Other intangible assets consist principally of customer lists and contractual rights. During the three months ended March 31, 2024, the Company recorded IPR&D of approximately $675.0 million as part of the Idorsia Transaction. Refer to Note 4 Acquisitions and Other Transactions for additional information. Amortization expense and intangible asset disposal & impairment charges (which are included as a component of amortization expense) are classified primarily within Cost of Sales in the condensed consolidated statements of operations and were as follows for the three months ended March 31, 2024 and 2023: Three Months Ended March 31, (In millions) 2024 2023 Intangible asset amortization expense $ 601.0 $ 603.3 Intangible asset disposal & impairment charges — 32.0 Total intangible asset amortization expense (including disposal & impairment charges) $ 601.0 $ 635.3 During the three months ended March 31, 2023, the Company recognized an intangible asset charge of approximately $32.0 million, which was recorded within Cost of Sales in the condensed consolidated statement of operations, to write down the disposal group to fair value, less cost to sell, related to our commercialization rights in the Upjohn Distributor Markets, which are classified as held for sale. Refer to Note 5 Divestitures for additional information. Intangible asset amortization expense over the remainder of 2024 and for the years ending December 31, 2025 through 2028 is estimated to be as follows: (In millions) 2024 $ 1,750 2025 2,255 2026 2,205 2027 2,006 2028 1,769

Financial Instruments and Risk

Financial Instruments and Risk Management	3 Months Ended
Financial Instruments and Risk Management	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments and Risk Management	Financial Instruments and Risk Management The Company is exposed to certain financial risks relating to its ongoing business operations. The primary financial risks that are managed by using derivative instruments are foreign currency risk and interest rate risk. Foreign Currency Risk Management In order to manage certain foreign currency risks, the Company enters into foreign exchange forward contracts to mitigate risk associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities. The foreign exchange forward contracts are measured at fair value and reported as current assets or current liabilities in the condensed consolidated balance sheets. Any gains or losses on the foreign exchange forward contracts are recognized in earnings in the period incurred in the condensed consolidated statements of operations. The Company has also entered into forward contracts to hedge forecasted foreign currency denominated sales from certain international subsidiaries and a portion of forecasted intercompany inventory sales denominated in Euro, Japanese Yen, Chinese Renminbi and Indian Rupee for up to twenty-four months. These contracts are designated as cash flow hedges to manage foreign currency transaction risk and are measured at fair value and reported as current assets or current liabilities in the condensed consolidated balance sheets. Any changes in the fair value of designated cash flow hedges are deferred in AOCE and are reclassified into earnings when the hedged item impacts earnings. Net Investment Hedges The Company may hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries by either borrowing directly in foreign currencies and designating all or a portion of the foreign currency debt as a hedge of the applicable net investment position or entering into foreign currency swaps that are designated as hedges of net investments. The Company has designated certain Euro and Yen borrowings as a hedge of its investment in certain Euro-functional and Yen-functional currency subsidiaries in order to manage foreign currency translation risk. Borrowings designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of AOCE until the sale or substantial liquidation of the underlying net investments. In addition, the Company manages the related foreign exchange risk of the Euro and Yen borrowings not designated as net investment hedges through certain Euro and Yen denominated financial assets and forward currency swaps. The following table summarizes the principal amounts of the Company’s outstanding Euro and Yen borrowings and the notional amounts of the Euro and Yen borrowings designated as net investment hedges: Notional Amount Designated as a Net Investment Hedge (In millions) Principal Amount March 31, December 31, 2.250% Euro Senior Notes due 2024 € 1,000.0 € 1,000.0 € 1,000.0 1.023% Euro Senior Notes due 2024 750.0 750.0 750.0 2.125% Euro Senior Notes due 2025 500.0 500.0 500.0 1.362% Euro Senior Notes due 2027 850.0 850.0 850.0 3.125% Euro Senior Notes due 2028 750.0 750.0 750.0 1.908% Euro Senior Notes due 2032 1,250.0 1,250.0 1,250.0 Foreign currency forward contracts 500.0 500.0 500.0 Euro Total € 5,600.0 € 5,600.0 € 5,600.0 Yen YEN Term Loan ¥ 40,000.0 ¥ 40,000.0 ¥ 40,000.0 Yen Total ¥ 40,000.0 ¥ 40,000.0 ¥ 40,000.0 At March 31, 2024, the principal amount of the Company’s outstanding Yen borrowings and the notional amount of the Yen borrowings designated as net investment hedges was $264.3 million. During the third quarter of 2023, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling Japanese Yen 14.6 billion with settlement dates through 2026. The transactions hedge a portion of the Company’s net investment in certain Yen-functional currency subsidiaries. All changes in the fair value of this derivative instrument, which is designated as a net investment hedge, are marked-to-market using the current spot exchange rate as of the end of the period. The portion of this change related to the excluded component will be amortized in interest expense over the life of the derivative while the remainder will be recorded in AOCE until the sale or substantial liquidation of the underlying net investments. The semiannual net interest payment received related to the fixed-rate component of the cross-currency interest rate swaps will be reflected in operating cash flows. During the fourth quarter of 2023, the Company executed foreign currency forward contracts with notional amounts totaling Euro 500 million with settlement dates in 2024. The transactions hedge a portion of the Company’s net investment in certain Euro functional currency subsidiaries. The contracts have been designated as a net investment hedge. During the second quarter of 2024, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling Euro 500 million with settlement dates through 2026. The transactions hedge a portion of the Company’s net investment in certain Euro-functional currency subsidiaries. All changes in the fair value of this derivative instrument, which is designated as a net investment hedge, are marked-to-market using the current spot exchange rate as of the end of the period. The portion of this change related to the excluded component will be amortized in interest expense over the life of the derivative while the remainder will be recorded in AOCE until the sale or substantial liquidation of the underlying net investments. The semiannual net interest payment received related to the fixed-rate component of the cross-currency interest rate swaps will be reflected in operating cash flows. Interest Rate Risk Management The Company enters into interest rate swaps from time to time in order to manage interest rate risk associated with the Company’s fixed-rate and floating-rate debt. Interest rate swaps that meet specific accounting criteria are accounted for as fair value or cash flow hedges. All derivative instruments used to manage interest rate risk are measured at fair value and reported as current assets or current liabilities in the condensed consolidated balance sheets. For fair value hedges, the changes in the fair value of both the hedging instrument and the underlying debt obligations are included in interest expense. For cash flow hedges, the change in fair value of the hedging instrument is deferred through AOCE and is reclassified into earnings when the hedged item impacts earnings. Cash Flow Hedging Relationships The Company’s interest rate swaps designated as cash flow hedges fix the interest rate on a portion of the Company’s variable-rate debt or hedge part of the Company’s interest rate exposure associated with the variability in the future cash flows attributable to changes in interest rates. Any changes in fair value are included in earnings or deferred through AOCE, depending on the nature and effectiveness of the offset. Any ineffectiveness in a cash flow hedging relationship is recognized immediately in earnings in the condensed consolidated statements of operations. Credit Risk Management The Company regularly reviews the creditworthiness of its financial counterparties and does not expect to incur a significant loss from the failure of any counterparties to perform under any agreements. The Company is not subject to any obligations to post collateral under derivative instrument contracts. Certain derivative instrument contracts entered into by the Company are governed by master agreements, which contain credit-risk-related contingent features that would allow the counterparties to terminate the contracts early and request immediate payment should the Company trigger an event of default on other specified borrowings. The Company records all derivative instruments on a gross basis in the condensed consolidated balance sheets. Accordingly, there are no offsetting amounts that net assets against liabilities. The following table summarizes the classification and fair values of derivative instruments in our condensed consolidated balance sheets: Asset Derivatives Liability Derivatives (In millions) Balance Sheet Location March 31, 2024 Fair Value December 31, 2023 Fair Value Balance Sheet Location March 31, 2024 Fair Value December 31, 2023 Fair Value Derivatives designated as hedges: Foreign currency forward contracts Prepaid expenses & other current assets $ 35.9 $ 17.5 Other current liabilities $ 10.0 $ 35.8 Total derivatives designated as hedges 35.9 17.5 10.0 35.8 Derivatives not designated as hedges: Foreign currency forward contracts Prepaid expenses & other current assets 37.4 88.7 Other current liabilities 60.1 88.8 Total derivatives not designated as hedges 37.4 88.7 60.1 88.8 Total derivatives $ 73.3 $ 106.2 $ 70.1 $ 124.6 The following table summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of Gains/(Losses) Recognized in Earnings Amount of Gains/(Losses) Recognized in AOCE (Net of Tax) on Derivatives Amount of Gains/(Losses) Reclassified from AOCE into Earnings Three months ended March 31, (In millions) Location of Gain/(Loss) 2024 2023 2024 2023 2024 2023 Derivative Financial Instruments in Cash Flow Hedging Relationships (1) : Foreign currency forward contracts Net sales (3) $ — $ — $ 24.8 $ 11.1 $ 6.6 $ 8.9 Interest rate swaps Interest expense (3) — — (1.2) (0.9) (1.6) (1.2) Derivative Financial Instruments in Net Investment Hedging Relationships: Cross-currency interest rate swaps Interest expense (2) 1.2 — 4.9 — — — Foreign currency forward contracts — — 10.7 — — — Non-derivative Financial Instruments in Net Investment Hedging Relationships: Foreign currency borrowings — — 117.0 (51.9) — — Derivative Financial Instruments Not Designated as Hedging Instruments: Foreign currency option and forward contracts Other (income) expense, net (2) (22.8) 44.6 — — — — Total $ (21.6) $ 44.6 $ 156.2 $ (41.7) $ 5.0 $ 7.7 ____________ (1) At March 31, 2024, the Company expects that approximately $3.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months. (2) Represents the location of the gain/(loss) recognized in earnings on derivatives. (3) Represents the location of the gain/(loss) reclassified from AOCE into earnings. Fair Value Measurement Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: • Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. • Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities. • Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value. Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above: March 31, 2024 December 31, 2023 (In millions) Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 500.3 $ — $ — $ 651.4 $ — $ — Total cash equivalents 500.3 — — 651.4 — — Equity securities: Exchange traded funds 51.9 — — 49.1 — — Marketable securities 0.2 — — 0.2 — — Total equity securities 52.1 — — 49.3 — — CCPS in Biocon Biologics — — 1,023.2 — — 976.3 Available-for-sale fixed income investments: Corporate bonds — 14.4 — — 15.9 — U.S. Treasuries — 14.2 — — 11.2 — Agency mortgage-backed securities — 3.2 — — 4.6 — Asset backed securities — 4.9 — — 5.1 — Other — 2.0 — — 0.2 — Total available-for-sale fixed income investments — 38.7 — — 37.0 — Foreign exchange derivative assets — 73.3 — — 106.2 — Total assets at recurring fair value measurement $ 552.4 $ 112.0 $ 1,023.2 $ 700.7 $ 143.2 $ 976.3 Financial Liabilities Foreign exchange derivative liabilities — 70.1 — — 124.6 — Contingent consideration — — 569.9 — — 215.1 Total liabilities at recurring fair value measurement $ — $ 70.1 $ 569.9 $ — $ 124.6 $ 215.1 For financial assets and liabilities that utilize Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including interest rate yield curves, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for the Company’s financial assets and liabilities: • Cash equivalents — valued at observable net asset value prices. • Equity securities, exchange traded funds — valued at the active quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in Other income, net in the condensed consolidated statements of operations. • Equity securities, marketable securities — valued using quoted stock prices from public exchanges at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in Other income, net in the condensed consolidated statements of operations. • CCPS in Biocon Biologics — valued using a Monte Carlo simulation model using Level 3 inputs. The fair value of the CCPS is sensitive to changes in the forecasts of operating metrics, changes in volatility and discount rates, and share dilution. The Company elected the fair value option for the CCPS under ASC 825. The fair value is reassessed quarterly and any change in the fair value estimate is recorded in Other income, net in the condensed consolidated statements of operations for that period. • Available-for-sale fixed income investments — valued at the quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value, net of income taxes, are included in accumulated other comprehensive loss as a component of shareholders’ equity. • Foreign exchange derivative assets and liabilities — valued using quoted forward foreign exchange prices and spot rates at the reporting date. Counterparties to these contracts are highly rated financial institutions. Contingent Consideration As of March 31, 2024, the Company had contingent consideration liability of $345 million related to the Idorsia Transaction. As of March 31, 2024 and December 31, 2023, the Company had a contingent consideration liability of $173.2 million and $177.6 million, respectively, related to the Respiratory Delivery Platform, and $30.0 million and $15.8 million, respectively, related to the Biocon Biologics Transaction. The measurement of these contingent consideration liabilities is calculated using unobservable Level 3 inputs based on the Company’s own assumptions primarily related to the probability and timing of future events and payments which are discounted using a market rate of return. At March 31, 2024, a discount rate of 8.5%, and at December 31, 2023, discount rates ranging from 6.4% and 8.0%, were utilized in the valuations. Significant changes in unobservable inputs could result in material changes to the contingent consideration liabilities. A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2023 to March 31, 2024 is as follows: (In millions) Current Portion (1) Long-Term Portion (2) Total Contingent Consideration Balance at December 31, 2023 $ 76.1 $ 139.0 $ 215.1 Acquisition — 345.0 345.0 Payments (10.9) — (10.9) Reclassifications 40.0 (40.0) — Accretion — 15.9 15.9 Fair value loss (3) — 4.8 4.8 Balance at March 31, 2024 $ 105.2 $ 464.7 $ 569.9 ____________ (1) Included in other current liabilities in the condensed consolidated balance sheets. (2) Included in other long-term obligations in the condensed consolidated balance sheets. (3) Included in litigation settlements and other contingencies, net in the condensed consolidated statements of operations. Although the Company has not elected the fair value option for financial assets and liabilities other than the CCPS, any future transacted financial asset or liability will be evaluated for the fair value election.

Debt

Debt	3 Months Ended
Debt	Mar. 31, 2024
Debt Disclosure [Abstract]
Debt	Debt For additional information, see Note 10 Debt in Viatris’ 2023 Form 10-K. Receivables Facility and Note Securitization Facility The Company has a $400 million Receivables Facility which expires in April 2025 and a $200 million Note Securitization Facility which expires in August 2024. Under the terms of each of the Receivables Facility and Note Securitization Facility, certain of our accounts receivable secure the amounts borrowed and cannot be used to pay our other debts or liabilities. The amount that we may borrow at a given point in time is determined based on the amount of qualifying accounts receivable that are present at such point in time. Amounts outstanding under either facility are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our condensed consolidated balance sheets. Long-Term Debt A summary of long-term debt is as follows: ($ in millions) Interest Rate as of March 31, 2024 March 31, December 31, Current portion of long-term debt: 2024 Euro Senior Notes 2.250 % 1,078.7 1,103.5 2024 Euro Senior Notes ** 1.023 % 810.9 831.5 Other 0.6 0.4 Deferred financing fees (0.5) (0.7) Current portion of long-term debt $ 1,889.7 $ 1,934.7 Non-current portion of long-term debt: 2025 Euro Senior Notes * 2.125 % 539.3 551.7 2025 Senior Notes * 1.650 % 754.8 755.7 2026 Senior Notes 3.950 % 2,245.6 2,245.1 2027 Euro Senior Notes ** 1.362 % 943.3 967.2 2027 Senior Notes * 2.300 % 768.4 769.8 2028 Euro Senior Notes ** 3.125 % 805.7 824.1 2028 Senior Notes * 4.550 % 749.1 749.1 2030 Senior Notes * 2.700 % 1,503.0 1,505.0 2032 Euro Senior Notes 1.908 % 1,442.4 1,478.4 2040 Senior Notes * 3.850 % 1,642.3 1,644.0 2043 Senior Notes * 5.400 % 497.5 497.5 2046 Senior Notes ** 5.250 % 999.9 999.9 2048 Senior Notes * 5.200 % 747.8 747.8 2050 Senior Notes *** 4.000 % 2,195.1 2,196.3 YEN Term Loan Facility Variable 264.3 283.6 Other 2.4 2.4 Deferred financing fees (28.4) (29.5) Long-term debt $ 16,072.5 $ 16,188.1 ____________ * Instrument was issued by Mylan Inc. Instrument was originally issued by Mylan N.V.; now held by Utah Acquisition Sub Inc. * Instrument was issued by Viatris Inc. **** Instrument was issued by Upjohn Finance B.V. At March 31, 2024 and December 31, 2023, the aggregate fair value of the Company’s outstanding notes was approximately $15.09 billion and $15.25 billion, respectively. The fair values of the outstanding notes were valued at quoted market prices from broker or dealer quotations and were classified as Level 2 in the fair value hierarchy. Mandatory minimum repayments remaining on the notional amount of outstanding long-term debt at March 31, 2024 were as follows for each of the periods ending December 31: (In millions) Total 2024 $ 1,888 2025 1,289 2026 2,514 2027 1,667 2028 1,559 Thereafter 8,549 Total $ 17,466

Comprehensive Earnings

Comprehensive Earnings	3 Months Ended
Comprehensive Earnings	Mar. 31, 2024
Equity [Abstract]
Comprehensive Earnings	Comprehensive Loss Accumulated other comprehensive loss, as reflected in the condensed consolidated balance sheets, is comprised of the following: (In millions) March 31, December 31, Accumulated other comprehensive loss: Net unrealized loss on available-for-sale fixed income securities, net of tax $ (1.4) $ (1.2) Net unrecognized gain and prior service cost related to defined benefit plans, net of tax 266.4 271.4 Net unrecognized gain (loss) on derivatives in cash flow hedging relationships, net of tax 13.6 (8.0) Net unrecognized gain on derivatives in net investment hedging relationships, net of tax 369.6 237.1 Foreign currency translation adjustment (3,589.2) (3,246.7) $ (2,941.0) $ (2,747.4) Components of accumulated other comprehensive loss, before tax, consist of the following, for the three months ended March 31, 2024 and 2023: Three Months Ended March 31, 2024 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Available-for-Sale Fixed Income Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2023, net of tax $ (8.0) $ 237.1 $ (1.2) $ 271.4 $ (3,246.7) $ (2,747.4) Other comprehensive earnings (loss) before reclassifications, before tax 33.7 169.1 (0.3) (2.4) (342.5) (142.4) Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax: Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales (6.6) (6.6) (6.6) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 1.6 1.6 1.6 Amortization of prior service costs included in SG&A 0.5 0.5 Amortization of actuarial gain included in SG&A (4.3) (4.3) Net other comprehensive earnings (loss), before tax 28.7 169.1 (0.3) (6.2) (342.5) (151.2) Income tax provision (benefit) 7.1 36.6 (0.1) (1.2) — 42.4 Balance at March 31, 2024, net of tax $ 13.6 $ 369.6 $ (1.4) $ 266.4 $ (3,589.2) $ (2,941.0) Three Months Ended March 31, 2023 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Available-for-Sale Fixed Income Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2022, net of tax $ (18.5) $ 377.0 $ (2.3) $ 268.5 $ (3,385.9) $ (2,761.2) Other comprehensive earnings (loss) before reclassifications, before tax 10.5 (66.2) 0.9 6.3 45.3 (3.2) Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax: Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales (8.9) (8.9) (8.9) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 1.2 1.2 1.2 Amortization of actuarial gain included in SG&A (5.0) (5.0) Net other comprehensive earnings (loss), before tax 2.8 (66.2) 0.9 1.3 45.3 (15.9) Income tax provision (benefit) 1.1 (14.3) 0.2 0.5 — (12.5) Balance at March 31, 2023, net of tax $ (16.8) $ 325.1 $ (1.6) $ 269.3 $ (3,340.6) $ (2,764.6)

Segment Information

Segment Information	3 Months Ended
Segment Information	Mar. 31, 2024
Segment Reporting [Abstract]
Segment Information	Segment Information Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its broad and diversified portfolio of branded and generic products, including complex products, to people in markets everywhere. Our Developed Markets segment comprises our operations primarily in North America and Europe. Our Greater China segment includes our operations in China, Taiwan and Hong Kong. Our JANZ segment reflects our operations in Japan, Australia and New Zealand. Our Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise. The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability. Certain costs are not included in the measurement of segment profitability, such as costs, if any, associated with the following: ◦ Intangible asset amortization expense and impairments of goodwill and long-lived assets; ◦ R&D and Acquired IPR&D expense; ◦ Net charges or net gains for litigation settlements and other contingencies; ◦ Certain costs related to transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory and property, plant and equipment; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) other significant items, which are substantive and/or unusual, and in some cases recurring, items (such as restructuring) that are evaluated on an individual basis by management and that either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such special items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for asset impairments and disposals of assets or businesses, including costs related to divestitures, and, as applicable, any associated transition activities. ◦ Corporate and other unallocated costs associated with platform functions (such as digital, facilities, legal, finance, human resources, insurance, public affairs and procurement), patient advocacy activities and certain compensation and other corporate costs (such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing, which include manufacturing variances associated with production) and operations that are not directly assessed to an operating segment as business unit (segment) management does not manage these costs. The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker. The accounting policies of the segments are the same as those described in Note 2 Summary of Significant Accounting Policies included in the 2023 Form 10-K. Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information. Net Sales Segment Profitability Three Months Ended March 31, Three Months Ended March 31, (In millions) 2024 2023 2024 2023 Reportable Segments: Developed Markets $ 2,165.4 $ 2,170.4 $ 913.3 $ 938.7 Greater China 543.9 564.6 366.3 394.3 JANZ 317.8 342.2 87.3 130.5 Emerging Markets 626.4 641.9 279.5 313.0 Total reportable segments $ 3,653.5 $ 3,719.1 $ 1,646.4 $ 1,776.5 Reconciling items: Intangible asset amortization expense (601.0) (603.3) Intangible asset disposal & impairment charges — (32.0) Globally managed research and development costs (199.7) (182.9) Acquired IPR&D (6.1) — Litigation settlements & other contingencies (76.8) (0.6) Transaction related and other special items (202.3) (178.5) Corporate and other unallocated (356.6) (379.4) Earnings from operations $ 203.9 $ 399.8

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Legislative Updates On August 16, 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (the “Inflation Reduction Act”) into law, which includes a new corporate alternative minimum tax (“CAMT”) and an excise tax of 1% on the fair market value of net stock repurchases. Both provisions are effective for years after December 31, 2022. The Company reflected the applicable estimated excise tax in treasury stock as part of the cost basis of the stock repurchased and recorded a corresponding liability in Other current liabilities in our condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023. The share repurchase and authorization amounts otherwise disclosed in this Form 10-Q exclude the excise tax. The Company does not anticipate being subject to the 15% CAMT tax in either 2023 or 2024 based on enacted law and regulatory guidance; however, our CAMT status could change in the future, depending on new regulations or regulatory guidance issued by the U.S. Department of the Treasury. In addition, many countries are actively considering or have proposed or enacted changes to their tax laws based on the Pillar Two Global Anti-Base Erosion Rules (“Pillar Two Rules”) proposed by the OECD. The Pillar Two Rules impose a global minimum tax of 15%, and under these rules, the Company may be required to pay a “top-up” tax to the extent our effective tax rate in any given country is below 15%. Several countries have enacted the Pillar Two Rules effective January 1, 2024, with many countries postponing implementation to January 1, 2025 or later, if at all. After determining which jurisdictions are not required to calculate a Pillar Two liability as a result of the existing safe harbors, the Company has determined that the impact of the Pillar Two Rules in the countries that have enacted such rules effective January 1, 2024, is not material to our results of operations for the three months ended March 31, 2024. While the Company is monitoring developments and evaluating the potential impact on future periods, we do not expect Pillar Two Rules to have a significant impact on the 2024 financial results. Tax Examinations The Company is subject to income taxes and tax audits in many jurisdictions. A certain degree of estimation is thus required in recording the assets and liabilities related to income taxes. Tax audits and examinations can involve complex issues, interpretations, and judgments and the resolution of matters that may span multiple years, particularly if subject to litigation or negotiation. Although the Company believes that adequate provisions have been made for these uncertain tax positions, the Company’s assessment of uncertain tax positions, including those arising from legal entity restructuring transactions in connection with the Combination, is based on estimates and assumptions that the Company believes are reasonable but the estimates for unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variations from such estimates could materially affect the Company’s financial condition, results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire. The Company is subject to ongoing IRS examinations. The years 2020 through 2022 are open years, with 2020 and 2021 under examination. Several international audits are currently in progress. In some cases, the tax auditors have proposed adjustments or issued assessments to our tax positions, including with respect to intercompany transactions, and we are in ongoing discussions with some of the auditors regarding the validity of their tax positions. In instances where assessments have been issued, we disagree with these assessments and believe they are without merit and incorrect as a matter of law. As a result, we anticipate that certain of these matters may become the subject of litigation before tax courts where we intend to vigorously defend our position. In Australia, the tax authorities have issued notices of assessments to the Company for the years ended December 2009 to December 2020, subject to additional interest and penalties, concerning our tax position with respect to certain intercompany transactions. The tax authorities denied our objections to the assessments for the years ended December 2009 to December 2020 and we have commenced litigation in the Australian Federal Court challenging those decisions. A trial took place in October 2023 and on March 20, 2024, the Court issued a decision in favor of the Company. The tax authorities did not appeal the Court decision. The Company made a partial payment of $56.0 million in 2021 and $5.2 million in 2022 in order to stay potential interest and penalties resulting from this litigation, which will be refunded, subject to currency exchange fluctuations, in future periods. In France, the tax authorities have issued notices of assessments to the Company for the years ended December 2013 to December 2015 concerning our tax position with respect to whether income earned by a Company entity not domiciled in France should be subject to French tax. We have commenced litigation before the French tax courts where the tax authorities will seek unpaid taxes, penalties, and interest. In India, the tax authorities have issued notices of assessments to the Company seeking unpaid taxes and interest for the financial years covering 2013 to 2018 concerning our tax position with respect to certain corporate tax deductions and certain intercompany transactions. Some of these issues were resolved through the Company entering into an agreement with the tax authorities in March 2023 in respect of the pricing of its international transactions. The Company recorded tax expense of approximately $22.3 million during 2023 due to the terms of this agreement. The remaining issues are in the audit phase or are being challenged in the Indian tax courts. In 2020, the Swedish Tax Authorities (“STA”) asserted an underpayment of tax against Meda A.B. for the tax years 2014 to 2019. The claim was that profits earned by its Luxembourg subsidiary should have been attributed to Meda A.B. The Company appealed the STA’s assessment to the Administrative Court of Stockholm. On September 16, 2022, the Court ruled in favor of Meda A.B. that no tax was due. The STA appealed that decision. On April 10, 2024, the Administrative Court of Appeals overturned the lower Court’s ruling and issued a decision in favor of the STA upholding its original assessment. The amount due including interest and penalties is approximately $19.0 million. The Company plans to file a petition seeking review of the decision to the Supreme Administrative Court. The Company has recorded a net reserve for uncertain tax positions of $281.8 million and $287.1 million, including interest and penalties, in connection with its international audits at March 31, 2024 and December 31, 2023, respectively. In connection with our international tax audits, it is possible that we will incur material losses above the amounts reserved. The Company’s major U.S. state taxing jurisdictions remain open from fiscal year 2013 through 2022, with several state audits currently in progress. The Company’s major international taxing jurisdictions remain open from 2012 through 2023. Accounting for Uncertainty in Income Taxes The impact of an uncertain tax position that is more likely than not of being sustained upon audit by the relevant taxing authority must be recognized at the largest amount that is more likely than not to be sustained. No portion of an uncertain tax position will be recognized if the position has less than a 50% likelihood of being sustained.

Litigation

Litigation	3 Months Ended
Litigation	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Litigation	Litigation

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

General (Policies)

General (Policies)	3 Months Ended
General (Policies)	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting Policy	The accompanying unaudited condensed consolidated financial statements (“interim financial statements”) of Viatris Inc. and subsidiaries were prepared in accordance with U.S. GAAP and the rules and regulations of the SEC for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in audited financial statements were condensed or omitted. The interim financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the interim results of operations, comprehensive loss, financial position, equity and cash flows for the periods presented.
Earnings per Share Policy	Basic earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period. Diluted earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive
Fair Value of Financial Instruments Policy	Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: • Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. • Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities. • Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.

Segment Information (Policies)

Segment Information (Policies)	3 Months Ended
Segment Information (Policies)	Mar. 31, 2024
Segment Reporting [Abstract]
Segment Reporting Policy	Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its broad and diversified portfolio of branded and generic products, including complex products, to people in markets everywhere. Our Developed Markets segment comprises our operations primarily in North America and Europe. Our Greater China segment includes our operations in China, Taiwan and Hong Kong. Our JANZ segment reflects our operations in Japan, Australia and New Zealand. Our Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise. The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability. Certain costs are not included in the measurement of segment profitability, such as costs, if any, associated with the following: ◦ Intangible asset amortization expense and impairments of goodwill and long-lived assets; ◦ R&D and Acquired IPR&D expense; ◦ Net charges or net gains for litigation settlements and other contingencies; ◦ Certain costs related to transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory and property, plant and equipment; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) other significant items, which are substantive and/or unusual, and in some cases recurring, items (such as restructuring) that are evaluated on an individual basis by management and that either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such special items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for asset impairments and disposals of assets or businesses, including costs related to divestitures, and, as applicable, any associated transition activities. ◦ Corporate and other unallocated costs associated with platform functions (such as digital, facilities, legal, finance, human resources, insurance, public affairs and procurement), patient advocacy activities and certain compensation and other corporate costs (such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing, which include manufacturing variances associated with production) and operations that are not directly assessed to an operating segment as business unit (segment) management does not manage these costs. The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker. The accounting policies of the segments are the same as those described in Note 2 Summary of Significant Accounting Policies included in the 2023 Form 10-K.

Revenue Recognition and Accou_2

Revenue Recognition and Accounts Receivable (Tables)	3 Months Ended
Revenue Recognition and Accounts Receivable (Tables)	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table presents the Company’s net sales by product category for each of our reportable segments for the three months ended March 31, 2024 and 2023, respectively: (In millions) Three Months Ended March 31, 2024 Product Category Developed Markets Greater China JANZ Emerging Markets Total Brands $ 1,178.8 $ 541.8 $ 184.1 $ 404.4 $ 2,309.1 Generics 986.6 2.1 133.7 222.0 1,344.4 Total Viatris $ 2,165.4 $ 543.9 $ 317.8 $ 626.4 $ 3,653.5 (In millions) Three Months Ended March 31, 2023 Product Category Developed Markets Greater China JANZ Emerging Markets Total Brands $ 1,232.0 $ 562.4 $ 190.3 $ 435.6 $ 2,420.3 Generics 938.4 2.2 151.9 206.3 1,298.8 Total Viatris $ 2,170.4 $ 564.6 $ 342.2 $ 641.9 $ 3,719.1 ____________ (a) Amounts for the three months ended March 31, 2024 include the impact of foreign currency translations compared to the prior year period. (b) Complex Gx , which were previously presented as a separate line item in the prior year period, are now included within Generics. Reclassifications were made to prior periods to conform to the current period presentation. The following table presents net sales on a consolidated basis for select key products for the three months ended March 31, 2024 and 2023, respectively: Three months ended March 31, (In millions) 2024 2023 Select Key Global Products Lipitor ® $ 388.9 $ 417.9 Norvasc ® 176.3 202.7 Lyrica ® 114.2 144.3 Viagra ® 100.7 115.0 EpiPen® Auto-Injectors 80.2 95.8 Creon ® 75.0 72.7 Celebrex ® 72.2 88.8 Effexor ® 59.4 64.6 Zoloft ® 58.0 56.5 Xalabrands 42.5 46.7 Select Key Segment Products Yupelri ® $ 55.2 $ 47.0 Dymista ® 48.2 53.2 Xanax ® 34.5 39.7 Amitiza ® 33.0 36.6 ____________ (a) The Company does not disclose net sales for any products considered competitively sensitive. (b) Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches. (c) Amounts for the three months ended March 31, 2024 include the impact of foreign currency translations compared to the prior year period. (d) Refer to intellectual property matters included in Note 17 Litigation for additional information regarding Yupelri® and Amitiza®. Variable Consideration and Accounts Receivable The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three months ended March 31, 2024 and 2023, respectively: Three Months Ended March 31, (In millions) 2024 2023 Gross sales $ 6,174.6 $ 6,273.0 Gross to net adjustments: Chargebacks (1,244.2) (1,350.7) Rebates, promotional programs and other sales allowances (1,048.3) (992.2) Returns (60.3) (50.4) Governmental rebate programs (168.3) (160.6) Total gross to net adjustments $ (2,521.1) $ (2,553.9) Net sales $ 3,653.5 $ 3,719.1
Schedule of Accounts Receivable, Net	Such allowances were comprised of the following at March 31, 2024 and December 31, 2023, respectively: (In millions) March 31, December 31, Accounts receivable, net $ 1,482.5 $ 1,483.6 Other current liabilities 1,008.8 996.3 Total $ 2,491.3 $ 2,479.9 Accounts receivable, net was comprised of the following at March 31, 2024 and December 31, 2023, respectively: (In millions) March 31, December 31, Trade receivables, net $ 2,790.0 $ 2,823.8 Other receivables 842.0 876.6 Accounts receivable, net $ 3,632.0 $ 3,700.4

Acquisitions and Other Transa_2

Acquisitions and Other Transactions (Tables)	3 Months Ended
Acquisitions and Other Transactions (Tables)	Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The preliminary allocation of the purchase price to the assets acquired and liabilities assumed is as follows: (In millions) Current assets $ 2.1 IPR&D 675.0 Goodwill 19.5 Total assets acquired $ 696.6 Current liabilities 1.6 Net assets acquired $ 695.0

Discontinued Operations and Dis

Discontinued Operations and Disposal Groups (Tables)	3 Months Ended
Discontinued Operations and Disposal Groups (Tables)	Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities Held for Sale	Assets and liabilities held for sale consisted of the following: (In millions) March 31, 2024 December 31, 2023 Assets held for sale Accounts receivable, net $ 57.6 $ 112.1 Inventories 408.9 422.4 Prepaid expenses and other current assets 5.0 7.5 Property, plant and equipment, net 239.0 262.2 Intangible assets, net 1,846.5 1,946.0 Goodwill 119.1 188.0 Other assets 3.3 5.1 Valuation allowance on assets held for sale (159.0) (157.3) Total assets held for sale $ 2,520.4 $ 2,786.0 Liabilities held for sale Accounts payable $ 126.2 $ 137.4 Other current liabilities 34.0 35.3 Deferred income tax liability 48.8 77.2 Other long-term obligations 25.8 25.2 Total liabilities held for sale $ 234.8 $ 275.1

Share-Based Incentive Plan (Tab

Share-Based Incentive Plan (Tables)	3 Months Ended
Share-Based Incentive Plan (Tables)	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock Awards Activity	The following table summarizes stock awards (stock options and SARs) activity: Number of Shares Under Stock Awards Weighted Average Exercise Price per Share Outstanding at December 31, 2023 4,159,333 $ 37.41 Exercised (18,012) 9.02 Forfeited (417,916) $ 53.13 Outstanding at March 31, 2024 3,723,405 $ 35.79 Vested and expected to vest at March 31, 2024 3,707,337 $ 35.90 Exercisable at March 31, 2024 3,597,026 $ 36.72
Nonvested Restricted Stock and Restricted Stock Unit Awards Activity	A rollforward of the changes in the Company’s nonvested Restricted Stock Awards (restricted stock and restricted stock unit awards, including PSUs) from December 31, 2023 to March 31, 2024 is presented below: Number of Restricted Stock Awards Weighted Average Grant-Date Fair Value Per Share Nonvested at December 31, 2023 31,096,783 $ 11.20 Granted 13,326,359 12.38 Released (10,336,912) 11.92 Forfeited (1,305,912) 11.00 Nonvested at March 31, 2024 32,780,318 $ 11.46

Pensions and Other Postretire_2

Pensions and Other Postretirement Benefits (Tables)	3 Months Ended
Pensions and Other Postretirement Benefits (Tables)	Mar. 31, 2024
Retirement Benefits [Abstract]
Net Periodic Benefit Cost	Components of net periodic benefit cost for the three months ended March 31, 2024 and 2023 were as follows: Pension and Other Postretirement Benefits Three Months Ended March 31, (In millions) 2024 2023 Service cost $ 7.9 $ 7.1 Interest cost 16.6 18.3 Expected return on plan assets (16.9) (16.4) Amortization of prior service costs 0.5 — Recognized net actuarial gains (4.3) (5.0) Net periodic benefit cost $ 3.8 $ 4.0

Balance Sheet Components (Table

Balance Sheet Components (Tables)	3 Months Ended
Balance Sheet Components (Tables)	Mar. 31, 2024
Balance Sheet Components [Abstract]
Schedule of Cash, cash equivalents, and restricted cash	Cash and restricted cash (In millions) March 31, December 31, March 31, 2023 Cash and cash equivalents $ 1,014.6 $ 991.9 $ 506.6 Restricted cash, included in prepaid expenses and other current assets 1.3 1.7 4.1 Cash, cash equivalents and restricted cash $ 1,015.9 $ 993.6 $ 510.7
Inventories	Inventories (In millions) March 31, December 31, Raw materials $ 686.7 $ 731.7 Work in process 1,097.5 602.1 Finished goods 2,039.0 2,135.9 Inventories $ 3,823.2 $ 3,469.7
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets (In millions) March 31, December 31, 2023 Prepaid expenses $ 178.9 $ 155.9 Deferred consideration due from Biocon Biologics 328.3 321.2 Available-for-sale fixed income securities 38.7 37.0 Fair value of financial instruments 73.3 106.2 Equity securities 52.1 49.3 Deferred charge for taxes on intercompany profit 701.8 747.3 Income tax receivable 310.7 340.2 Other current assets 249.5 271.0 Prepaid expenses and other current assets $ 1,933.3 $ 2,028.1
Property, Plant and Equipment	Property, plant and equipment, net (In millions) March 31, December 31, 2023 Machinery and equipment $ 2,745.8 $ 2,774.5 Buildings and improvements 1,438.8 1,444.4 Construction in progress 406.5 431.2 Land and improvements 114.6 120.2 Gross property, plant and equipment 4,705.7 4,770.3 Accumulated depreciation 1,997.5 2,010.7 Property, plant and equipment, net $ 2,708.2 $ 2,759.6
Other Assets	Other assets (In millions) March 31, December 31, 2023 Non-marketable equity investments $ 165.7 $ 165.7 CCPS in Biocon Biologics 1,023.2 976.3 Operating lease right-of-use assets 242.1 245.6 Other long-term assets 800.6 821.1 Other assets $ 2,231.6 $ 2,208.7
Accounts payable	Accounts payable (In millions) March 31, December 31, 2023 Trade accounts payable $ 1,584.0 $ 1,381.4 Other payables 612.9 556.8 Accounts payable $ 2,196.9 $ 1,938.2
Other Current Liabilities	Other current liabilities (In millions) March 31, December 31, 2023 Accrued sales allowances $ 1,008.8 $ 996.3 Legal and professional accruals, including litigation accruals 321.6 244.0 Payroll and employee benefit liabilities 598.2 844.5 Contingent consideration (1) 105.2 76.1 Accrued restructuring 29.9 36.4 Accrued interest 204.7 66.8 Fair value of financial instruments 70.1 124.6 Operating lease liability 91.8 83.0 Other 851.4 922.2 Other current liabilities $ 3,281.7 $ 3,393.9
Other Noncurrent Liabilities	Other long-term obligations (In millions) March 31, December 31, 2023 Employee benefit liabilities $ 495.1 $ 504.3 Contingent consideration (2) 464.7 139.0 Tax related items, including contingencies 406.3 399.3 Operating lease liability 156.2 165.4 Accrued restructuring 57.9 59.2 Other 244.9 249.7 Other long-term obligations $ 1,825.1 $ 1,516.9

Earnings (Loss) per Ordinary _2

Earnings (Loss) per Ordinary Share (Tables)	3 Months Ended
Earnings (Loss) per Ordinary Share (Tables)	Mar. 31, 2024
Earnings Per Share [Abstract]
Basic and Diluted Earnings per Ordinary Share Attributable to Mylan N.V.	Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows: Three Months Ended March 31, (In millions, except per share amounts) 2024 2023 Basic earnings attributable to Viatris Inc. common shareholders (numerator): Net earnings attributable to Viatris Inc. common shareholders $ 113.9 $ 224.7 Shares (denominator): Weighted average shares outstanding 1,195.2 1,202.5 Basic earnings per share attributable to Viatris Inc. shareholders $ 0.10 $ 0.19 Diluted earnings attributable to Viatris Inc. common shareholders (numerator): Net earnings attributable to Viatris Inc. common shareholders $ 113.9 $ 224.7 Shares (denominator): Weighted average shares outstanding 1,195.2 1,202.5 Share-based awards 14.3 3.1 Total dilutive shares outstanding 1,209.5 1,205.6 Diluted earnings per share attributable to Viatris Inc. shareholders $ 0.09 $ 0.19

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
Goodwill and Intangible Assets (Tables)	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the three months ended March 31, 2024 are as follows: (In millions) Developed Markets (1) Greater China JANZ (2) Emerging Markets (3) Total Balance at December 31, 2023: 7,107.4 932.8 645.7 1,181.2 9,867.1 Acquisitions 19.5 — — — 19.5 Foreign currency translation (153.5) (7.5) (24.6) (7.5) (193.1) Balance at March 31, 2024: $ 6,973.4 $ 925.3 $ 621.1 $ 1,173.7 $ 9,693.5 ____________ (1) Balances as of March 31, 2024 and December 31, 2023 include an accumulated impairment loss of $929.0 million. (2) Balances as of March 31, 2024 and December 31, 2023 include an accumulated impairment loss of $30.0 million. (3) Balances as of March 31, 2024 and December 31, 2023 include an accumulated impairment loss of $124.0 million.
Components of Intangible Assets	Intangible assets consist of the following components at March 31, 2024 and December 31, 2023: (In millions) Weighted Average Life (Years) Original Cost Accumulated Amortization Net Book Value March 31, 2024 Product rights, licenses and other (1) 13 $ 33,830.4 $ 15,690.8 $ 18,139.6 In-process research and development 994.1 — 994.1 $ 34,824.5 $ 15,690.8 $ 19,133.7 December 31, 2023 Product rights, licenses and other (1) 13 $ 34,178.1 $ 15,316.4 $ 18,861.7 In-process research and development 319.4 — 319.4 $ 34,497.5 $ 15,316.4 $ 19,181.1 ____________ (1)
Finite-lived Intangible Assets Amortization Expense	Three Months Ended March 31, (In millions) 2024 2023 Intangible asset amortization expense $ 601.0 $ 603.3 Intangible asset disposal & impairment charges — 32.0 Total intangible asset amortization expense (including disposal & impairment charges) $ 601.0 $ 635.3 During the three months ended March 31, 2023, the Company recognized an intangible asset charge of approximately $32.0 million, which was recorded within Cost of Sales in the condensed consolidated statement of operations, to write down the disposal group to fair value, less cost to sell, related to our commercialization rights in the Upjohn Distributor Markets, which are classified as held for sale. Refer to Note 5 Divestitures for additional information.
Expected Amortization Expense	Intangible asset amortization expense over the remainder of 2024 and for the years ending December 31, 2025 through 2028 is estimated to be as follows: (In millions) 2024 $ 1,750 2025 2,255 2026 2,205 2027 2,006 2028 1,769

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	3 Months Ended
Financial Instruments and Risk Management (Tables)	Mar. 31, 2024
Derivatives, Fair Value [Line Items]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The following table summarizes the classification and fair values of derivative instruments in our condensed consolidated balance sheets: Asset Derivatives Liability Derivatives (In millions) Balance Sheet Location March 31, 2024 Fair Value December 31, 2023 Fair Value Balance Sheet Location March 31, 2024 Fair Value December 31, 2023 Fair Value Derivatives designated as hedges: Foreign currency forward contracts Prepaid expenses & other current assets $ 35.9 $ 17.5 Other current liabilities $ 10.0 $ 35.8 Total derivatives designated as hedges 35.9 17.5 10.0 35.8 Derivatives not designated as hedges: Foreign currency forward contracts Prepaid expenses & other current assets 37.4 88.7 Other current liabilities 60.1 88.8 Total derivatives not designated as hedges 37.4 88.7 60.1 88.8 Total derivatives $ 73.3 $ 106.2 $ 70.1 $ 124.6
Financial Assets and Liabilities Carried at Fair Value	Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above: March 31, 2024 December 31, 2023 (In millions) Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 500.3 $ — $ — $ 651.4 $ — $ — Total cash equivalents 500.3 — — 651.4 — — Equity securities: Exchange traded funds 51.9 — — 49.1 — — Marketable securities 0.2 — — 0.2 — — Total equity securities 52.1 — — 49.3 — — CCPS in Biocon Biologics — — 1,023.2 — — 976.3 Available-for-sale fixed income investments: Corporate bonds — 14.4 — — 15.9 — U.S. Treasuries — 14.2 — — 11.2 — Agency mortgage-backed securities — 3.2 — — 4.6 — Asset backed securities — 4.9 — — 5.1 — Other — 2.0 — — 0.2 — Total available-for-sale fixed income investments — 38.7 — — 37.0 — Foreign exchange derivative assets — 73.3 — — 106.2 — Total assets at recurring fair value measurement $ 552.4 $ 112.0 $ 1,023.2 $ 700.7 $ 143.2 $ 976.3 Financial Liabilities Foreign exchange derivative liabilities — 70.1 — — 124.6 — Contingent consideration — — 569.9 — — 215.1 Total liabilities at recurring fair value measurement $ — $ 70.1 $ 569.9 $ — $ 124.6 $ 215.1
Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)	The following table summarizes the principal amounts of the Company’s outstanding Euro and Yen borrowings and the notional amounts of the Euro and Yen borrowings designated as net investment hedges: Notional Amount Designated as a Net Investment Hedge (In millions) Principal Amount March 31, December 31, 2.250% Euro Senior Notes due 2024 € 1,000.0 € 1,000.0 € 1,000.0 1.023% Euro Senior Notes due 2024 750.0 750.0 750.0 2.125% Euro Senior Notes due 2025 500.0 500.0 500.0 1.362% Euro Senior Notes due 2027 850.0 850.0 850.0 3.125% Euro Senior Notes due 2028 750.0 750.0 750.0 1.908% Euro Senior Notes due 2032 1,250.0 1,250.0 1,250.0 Foreign currency forward contracts 500.0 500.0 500.0 Euro Total € 5,600.0 € 5,600.0 € 5,600.0 Yen YEN Term Loan ¥ 40,000.0 ¥ 40,000.0 ¥ 40,000.0 Yen Total ¥ 40,000.0 ¥ 40,000.0 ¥ 40,000.0
Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations	The following table summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of Gains/(Losses) Recognized in Earnings Amount of Gains/(Losses) Recognized in AOCE (Net of Tax) on Derivatives Amount of Gains/(Losses) Reclassified from AOCE into Earnings Three months ended March 31, (In millions) Location of Gain/(Loss) 2024 2023 2024 2023 2024 2023 Derivative Financial Instruments in Cash Flow Hedging Relationships (1) : Foreign currency forward contracts Net sales (3) $ — $ — $ 24.8 $ 11.1 $ 6.6 $ 8.9 Interest rate swaps Interest expense (3) — — (1.2) (0.9) (1.6) (1.2) Derivative Financial Instruments in Net Investment Hedging Relationships: Cross-currency interest rate swaps Interest expense (2) 1.2 — 4.9 — — — Foreign currency forward contracts — — 10.7 — — — Non-derivative Financial Instruments in Net Investment Hedging Relationships: Foreign currency borrowings — — 117.0 (51.9) — — Derivative Financial Instruments Not Designated as Hedging Instruments: Foreign currency option and forward contracts Other (income) expense, net (2) (22.8) 44.6 — — — — Total $ (21.6) $ 44.6 $ 156.2 $ (41.7) $ 5.0 $ 7.7 ____________ (1) At March 31, 2024, the Company expects that approximately $3.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months. (2) Represents the location of the gain/(loss) recognized in earnings on derivatives. (3) Represents the location of the gain/(loss) reclassified from AOCE into earnings.
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2023 to March 31, 2024 is as follows: (In millions) Current Portion (1) Long-Term Portion (2) Total Contingent Consideration Balance at December 31, 2023 $ 76.1 $ 139.0 $ 215.1 Acquisition — 345.0 345.0 Payments (10.9) — (10.9) Reclassifications 40.0 (40.0) — Accretion — 15.9 15.9 Fair value loss (3) — 4.8 4.8 Balance at March 31, 2024 $ 105.2 $ 464.7 $ 569.9 ____________ (1) Included in other current liabilities in the condensed consolidated balance sheets. (2) Included in other long-term obligations in the condensed consolidated balance sheets. (3) Included in litigation settlements and other contingencies, net in the condensed consolidated statements of operations.

Debt (Tables)

Debt (Tables)	3 Months Ended
Debt (Tables)	Mar. 31, 2024
Debt Disclosure [Abstract]
Summary of Long-Term Debt	A summary of long-term debt is as follows: ($ in millions) Interest Rate as of March 31, 2024 March 31, December 31, Current portion of long-term debt: 2024 Euro Senior Notes 2.250 % 1,078.7 1,103.5 2024 Euro Senior Notes ** 1.023 % 810.9 831.5 Other 0.6 0.4 Deferred financing fees (0.5) (0.7) Current portion of long-term debt $ 1,889.7 $ 1,934.7 Non-current portion of long-term debt: 2025 Euro Senior Notes * 2.125 % 539.3 551.7 2025 Senior Notes * 1.650 % 754.8 755.7 2026 Senior Notes 3.950 % 2,245.6 2,245.1 2027 Euro Senior Notes ** 1.362 % 943.3 967.2 2027 Senior Notes * 2.300 % 768.4 769.8 2028 Euro Senior Notes ** 3.125 % 805.7 824.1 2028 Senior Notes * 4.550 % 749.1 749.1 2030 Senior Notes * 2.700 % 1,503.0 1,505.0 2032 Euro Senior Notes 1.908 % 1,442.4 1,478.4 2040 Senior Notes * 3.850 % 1,642.3 1,644.0 2043 Senior Notes * 5.400 % 497.5 497.5 2046 Senior Notes ** 5.250 % 999.9 999.9 2048 Senior Notes * 5.200 % 747.8 747.8 2050 Senior Notes *** 4.000 % 2,195.1 2,196.3 YEN Term Loan Facility Variable 264.3 283.6 Other 2.4 2.4 Deferred financing fees (28.4) (29.5) Long-term debt $ 16,072.5 $ 16,188.1 ____________ * Instrument was issued by Mylan Inc. Instrument was originally issued by Mylan N.V.; now held by Utah Acquisition Sub Inc. * Instrument was issued by Viatris Inc. **** Instrument was issued by Upjohn Finance B.V.
Minimum Repayments on Outstanding Borrowings	Mandatory minimum repayments remaining on the notional amount of outstanding long-term debt at March 31, 2024 were as follows for each of the periods ending December 31: (In millions) Total 2024 $ 1,888 2025 1,289 2026 2,514 2027 1,667 2028 1,559 Thereafter 8,549 Total $ 17,466

Comprehensive Earnings (Tables)

Comprehensive Earnings (Tables)	3 Months Ended
Comprehensive Earnings (Tables)	Mar. 31, 2024
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss, as reflected in the condensed consolidated balance sheets, is comprised of the following: (In millions) March 31, December 31, Accumulated other comprehensive loss: Net unrealized loss on available-for-sale fixed income securities, net of tax $ (1.4) $ (1.2) Net unrecognized gain and prior service cost related to defined benefit plans, net of tax 266.4 271.4 Net unrecognized gain (loss) on derivatives in cash flow hedging relationships, net of tax 13.6 (8.0) Net unrecognized gain on derivatives in net investment hedging relationships, net of tax 369.6 237.1 Foreign currency translation adjustment (3,589.2) (3,246.7) $ (2,941.0) $ (2,747.4)
Components of Other Comprehensive Loss	Components of accumulated other comprehensive loss, before tax, consist of the following, for the three months ended March 31, 2024 and 2023: Three Months Ended March 31, 2024 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Available-for-Sale Fixed Income Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2023, net of tax $ (8.0) $ 237.1 $ (1.2) $ 271.4 $ (3,246.7) $ (2,747.4) Other comprehensive earnings (loss) before reclassifications, before tax 33.7 169.1 (0.3) (2.4) (342.5) (142.4) Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax: Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales (6.6) (6.6) (6.6) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 1.6 1.6 1.6 Amortization of prior service costs included in SG&A 0.5 0.5 Amortization of actuarial gain included in SG&A (4.3) (4.3) Net other comprehensive earnings (loss), before tax 28.7 169.1 (0.3) (6.2) (342.5) (151.2) Income tax provision (benefit) 7.1 36.6 (0.1) (1.2) — 42.4 Balance at March 31, 2024, net of tax $ 13.6 $ 369.6 $ (1.4) $ 266.4 $ (3,589.2) $ (2,941.0) Three Months Ended March 31, 2023 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Available-for-Sale Fixed Income Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2022, net of tax $ (18.5) $ 377.0 $ (2.3) $ 268.5 $ (3,385.9) $ (2,761.2) Other comprehensive earnings (loss) before reclassifications, before tax 10.5 (66.2) 0.9 6.3 45.3 (3.2) Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax: Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales (8.9) (8.9) (8.9) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 1.2 1.2 1.2 Amortization of actuarial gain included in SG&A (5.0) (5.0) Net other comprehensive earnings (loss), before tax 2.8 (66.2) 0.9 1.3 45.3 (15.9) Income tax provision (benefit) 1.1 (14.3) 0.2 0.5 — (12.5) Balance at March 31, 2023, net of tax $ (16.8) $ 325.1 $ (1.6) $ 269.3 $ (3,340.6) $ (2,764.6)

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
Segment Information (Tables)	Mar. 31, 2024
Segment Reporting [Abstract]
Reconciliation of Segment Information to Total Consolidated Information	Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information. Net Sales Segment Profitability Three Months Ended March 31, Three Months Ended March 31, (In millions) 2024 2023 2024 2023 Reportable Segments: Developed Markets $ 2,165.4 $ 2,170.4 $ 913.3 $ 938.7 Greater China 543.9 564.6 366.3 394.3 JANZ 317.8 342.2 87.3 130.5 Emerging Markets 626.4 641.9 279.5 313.0 Total reportable segments $ 3,653.5 $ 3,719.1 $ 1,646.4 $ 1,776.5 Reconciling items: Intangible asset amortization expense (601.0) (603.3) Intangible asset disposal & impairment charges — (32.0) Globally managed research and development costs (199.7) (182.9) Acquired IPR&D (6.1) — Litigation settlements & other contingencies (76.8) (0.6) Transaction related and other special items (202.3) (178.5) Corporate and other unallocated (356.6) (379.4) Earnings from operations $ 203.9 $ 399.8

Revenue Recognition and Accou_3

Revenue Recognition and Accounts Receivable (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Proceeds from sale and collection of receivables	$ 64.2	$ 30.8

Revenue Recognition and Accou_4

Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Net sales	$ 3,653.5	$ 3,719.1
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,309.1	2,420.3
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,344.4	1,298.8
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	388.9	417.9
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	176.3	202.7
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	114.2	144.3
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	100.7	115
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	80.2	95.8
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	72.2	88.8
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	59.4	64.6
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	58	56.5
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	75	72.7
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	42.5	46.7
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	33	36.6
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	34.5	39.7
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	48.2	53.2
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	55.2	47
Developed Markets Segment \| Brands
Disaggregation of Revenue [Line Items]
Net sales	1,178.8	1,232
Developed Markets Segment \| Generics
Disaggregation of Revenue [Line Items]
Net sales	986.6	938.4
Greater China \| Brands
Disaggregation of Revenue [Line Items]
Net sales	541.8	562.4
Greater China \| Generics
Disaggregation of Revenue [Line Items]
Net sales	2.1	2.2
Japan, Australia and New Zealand Segment \| Brands
Disaggregation of Revenue [Line Items]
Net sales	184.1	190.3
Japan, Australia and New Zealand Segment \| Generics
Disaggregation of Revenue [Line Items]
Net sales	133.7	151.9
Emerging Markets Segment \| Brands
Disaggregation of Revenue [Line Items]
Net sales	404.4	435.6
Emerging Markets Segment \| Generics
Disaggregation of Revenue [Line Items]
Net sales	222	206.3
Operating Segment \| Developed Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	2,165.4	2,170.4
Operating Segment \| Greater China
Disaggregation of Revenue [Line Items]
Net sales	543.9	564.6
Operating Segment \| Japan, Australia and New Zealand Segment
Disaggregation of Revenue [Line Items]
Net sales	317.8	342.2
Operating Segment \| Emerging Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 626.4	$ 641.9

Revenue Recognition and Accou_5

Revenue Recognition and Accounts Receivable Variable Consideration (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Gross sales	$ 6,174.6	$ 6,273
Chargebacks	(1,244.2)	(1,350.7)
Rebates, promotional programs and other sales allowances	(1,048.3)	(992.2)
Returns	(60.3)	(50.4)
Medicaid and other governmental rebates	(168.3)	(160.6)
Sales Revenue, Gross to net adjustments	(2,521.1)	(2,553.9)
Net sales	$ 3,653.5	$ 3,719.1

Revenue Recognition and Accou_6

Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Revenue Recognition And Accounts Receivable [Line Items]
Trade receivables, net	$ 2,790	$ 2,823.8
Other receivables	842	876.6
Accounts receivable, net	3,632	3,700.4
Transfers of Financial Assets Accounted for as Sale, Initial Fair Value of Assets Obtained as Proceeds	285.6	415.7
Variable Consideration
Revenue Recognition And Accounts Receivable [Line Items]
Trade receivables, net	1,482.5	1,483.6
Other receivables	1,008.8	996.3
Accounts receivable, net	$ 2,491.3	$ 2,479.9

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements Recent Accounting Pronouncements (Impact of Adoption - ASU 2014-09) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of sales	$ 2,159.4	$ 2,186.9
Income tax provision	90.7	98
Net earnings attributable to Viatris Inc. common shareholders	113.9	224.7
Revenues	3,663.4	$ 3,729.1
Prepaid expenses and other current assets	1,933.3		$ 2,028.1
Income taxes payable	148.4		226.8
Retained earnings	4,607.5		4,639.7
Accumulated other comprehensive loss	$ (2,941)		$ (2,747.4)

Acquisitions and Other Transa_3

Acquisitions and Other Transactions (Narrative) (Details) $ in Millions		3 Months Ended
	Mar. 15, 2024 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Nov. 07, 2022 USD ($)
Business Acquisition [Line Items]
Goodwill		$ 9,693.5		$ 9,867.1
Contingent consideration (1)		569.9		$ 215.1
Payments to Acquire Businesses, Net of Cash Acquired		350	$ 667.7
Revenues		3,663.4	3,729.1
Net earnings attributable to Viatris Inc. common shareholders		$ 113.9	$ 224.7
Acquisitions and Other Transactions		Acquisitions and Other Transactions Idorsia On March 15, 2024, the Company acquired the development programs and certain personnel related to selatogrel and cenerimod from Idorsia in exchange for an upfront payment to Idorsia of $350 million, potential milestone payments (including $300 million payable upon the achievement of certain development and regulatory milestones, and $2.1 billion payable upon the achievement of certain tiered sales milestones), as well as potential contingent tiered sales royalties. Viatris and Idorsia are both contributing to the development costs for both programs. Viatris has worldwide commercialization rights for both selatogrel and cenerimod (excluding, for cenerimod only, Japan, South Korea and certain countries in the Asia-Pacific region). A joint development committee is overseeing the development of the ongoing Phase 3 programs through regulatory approval. The agreements also provide Viatris a right of first refusal and a right of first negotiation for certain other assets in Idorsia’s pipeline. The transaction expands our portfolio of innovative assets by adding two Phase 3 assets and combines our financial strength and worldwide operational infrastructure with Idorsia’s proven, highly-productive drug development team and innovation engine. In accordance with U.S. GAAP, the transaction has been accounted for as a business combination under the acquisition method of accounting. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. During the three months ended March 31, 2024, the Company incurred acquisition-related costs of approximately $0.3 million, which were recorded primarily in SG&A in the condensed consolidated statements of operations. The U.S. GAAP purchase price allocated to the transaction was $695 million, which consisted of $350 million of cash consideration paid and estimated contingent consideration at the date of acquisition valued at approximately $345 million. The fair value of the contingent consideration was valued using a Monte Carlo simulation model using Level 3 inputs. The fair value is sensitive to changes in the forecasts of operating metrics, probability of success, and discount rates. Refer to Note 11, Financial Instruments and Risk Management , for additional information. The preliminary allocation of the purchase price to the assets acquired and liabilities assumed is as follows: (In millions) Current assets $ 2.1 IPR&D 675.0 Goodwill 19.5 Total assets acquired $ 696.6 Current liabilities 1.6 Net assets acquired $ 695.0 The preliminary fair value estimates for the assets acquired and liabilities assumed were based upon preliminary calculations, valuations and assumptions that are subject to change as the Company obtains additional information during the measurement period (up to one year from the acquisition date). The primary areas subject to change relate to the finalization of the valuation of IPR&D, contingent consideration, and income taxes. The amount allocated to IPR&D represents an estimate of the fair value of purchased in-process technology for research projects that, as of the closing date of the acquisition, had not reached technological feasibility and had no alternative future use. The fair value of IPR&D of $675 million was based on the excess earnings method, which utilizes forecasts of expected cash inflows (including estimates for ongoing costs) and other contributory charges. A discount rate of 20% was utilized to discount net cash inflows to present values. IPR&D is accounted for as an indefinite-lived intangible asset and will be subject to impairment testing until completion or abandonment of the projects. Upon successful completion and launch of each product, the Company will make a determination of the estimated useful life of the individual asset. Viatris and Idorsia will both contribute to the development costs for both programs, which are expected to be incurred through 2026. There are risks and uncertainties associated with the timely and successful completion of the projects included in IPR&D, and no assurances can be given that the underlying assumptions used to estimate the fair value of IPR&D will not change or the timely completion of each project to commercial success will occur. The goodwill of $19.5 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is currently expected to be deductible for income tax purposes. The acquisition did not have a material impact on the Company’s results of operations since the acquisition date or on a pro forma basis for the three months ended March 31, 2024 and 2023.
Measurement Input, Discount Rate
Business Acquisition [Line Items]
Business Combination, Fair Value, In Process Research And Development, Measurement Input	0.20
Famy Life Sciences Acquisition
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired					$ 695
Idorsia Pharmaceuticals Ltd.
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs		$ 0.3
Goodwill	$ 19.5
Contingent consideration (1)		$ 345
Payments to Acquire Businesses, Net of Cash Acquired	695
Business Combination, Contingent Consideration, Liability, Milestone Payment Payable Upon Development And Regulatory Milestones	300
Business Combination, Contingent Consideration, Liability, Milestone Payment Payable Upon Achievement Of Tiered Sales Milestones	2,100
Business Combination, Price of Acquisition, Expected	$ 350

Acquisitions and Other Transa_4

Acquisitions and Other Transactions (Purchase Price Allocations) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Mar. 15, 2024	Dec. 31, 2023	Nov. 07, 2022
Business Acquisition [Line Items]
Goodwill	$ 9,693.5		$ 9,867.1
Famy Life Sciences Acquisition
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				$ 695
Idorsia Pharmaceuticals Ltd.
Business Acquisition [Line Items]
Current assets (excluding inventories and net of cash acquired)		$ 2.1
Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, In Process Research And Development		675
Goodwill		19.5
Total assets acquired		696.6
Current liabilities		(1.6)
Payments to Acquire Businesses, Net of Cash Acquired		$ 695

Divestitures (Details)

Divestitures (Details) $ in Millions		3 Months Ended				12 Months Ended
Divestitures (Details) $ in Millions	Nov. 29, 2022 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Oct. 01, 2023 product
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets and subsidiaries		$ 240.6		$ 0
Other Nonoperating Income (Expense)		139.1		69.9
Gain (Loss) on Disposition of Business		70.4		0
Biocon Biologics
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Equity Securities, FV-NI, Gain (Loss)		(46.9)		2.6
Licensing Agreements
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Write down of intangible assets				32	$ 172.9
Disposal Group, Held-for-Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets held for sale		1,846.5	$ 1,946				$ 1,946
Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number Of Women's Healthcare Products Sold \| product								2
Upjohn Distributor Markets \| Disposal Group, Held-for-Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset Impairment Charges					374.2		136.4
Inventory Valuation Reserves				9.2
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal							85.2
Upjohn Distributor Markets \| Disposal Group, Held-for-Sale, Not Discontinued Operations \| Inventories
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset Impairment Charges					84.3
Upjohn Distributor Markets \| Disposal Group, Held-for-Sale, Not Discontinued Operations \| Emerging Markets Segment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Goodwill, Impairment Loss					$ 117
Biocon Biologics
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Other Nonoperating Income (Expense)		13.4		$ 45.7
Biocon Biologics \| Scenario, Forecast \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture of Business, Deferred Cash Consideration.						$ 335
Biocon Biologics \| Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration	$ 3,000
Proceeds from sale of assets and subsidiaries	2,000
Noncash or Part Noncash Divestiture, Amount of Consideration Received	$ 1,000
Disposal Group, Including Discontinued Operation, Ownership Percentage in Disposed Asset	12.90%
Disposal Group, Including Discontinued Operations, Contingent Consideration Liability, Working Capital Adjustment	$ 250
Disposal Group, Including Discontinued Operations, Contingent Consideration Paid							220
Women's Health Products \| Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Other Income
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Disposition of Business							80.8
Women's Health Products \| Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Selling, General and Administrative Expenses
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Disposition of Business							$ 156.2
OTC Business \| Disposal Group, Held-for-Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset Impairment Charges			734.7
Goodwill, Impairment Loss			580.1
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down			$ 154.7
API Business \| Disposal Group, Held-for-Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down		$ 10.4

Divestitures (Details)_2

Divestitures (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Valuation allowance on assets held for sale		$ (157.3)
Assets held for sale	$ 2,520.4	2,786
Liabilities held for sale	234.8	275.1
Disposal Group, Held-for-Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net	57.6	112.1
Inventories	408.9	422.4
Prepaid expenses and other current assets	5	7.5
Property, plant and equipment, net	239	262.2
Goodwill	1,846.5	1,946
Goodwill	119.1	188
Other assets	3.3	5.1
Valuation allowance on assets held for sale	(159)
Accounts payable	126.2	137.4
Other current liabilities	34	35.3
Deferred income tax liability	48.8	77.2
Other long-term obligations	$ 25.8	25.2
Liabilities held for sale		$ 275.1

Share-Based Incentive Plan (Nar

Share-Based Incentive Plan (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Nov. 16, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	18,012
Stock option award expiration period, in years	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,723,405		4,159,333
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested	$ 0.8
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	0.4
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value	0.8
Long-Term Incentive Plan 2003
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation expense, net of estimated forfeitures	$ 287.6
Weighted-average period over which total unrecognized compensation expense expected to be recognized, in years	1 year 9 months 18 days
Intrinsic value of stock-based awards exercised and restricted stock units converted	$ 129	$ 100.8
Long-Term Incentive Plan 2003 \| Stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average remaining contractual term for stock awards outstanding, in years	3 years 9 months 18 days
Average remaining contractual term for stock awards vested and expected to vest, in years	3 years 8 months 12 days
Average remaining contractual term for stock awards exercisable, in years	3 years 7 months 6 days
Long-Term Incentive Plan 2003 \| Stock awards \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years	3 years
Long-Term Incentive Plan 2003 \| Stock awards \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years	4 years
2020 Stock Incentive Plan and 2003 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares reserved for issuance				72,500,000

Share-Based Incentive Plan (Sto

Share-Based Incentive Plan (Stock Awards) (Details) - $ / shares	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 35.79	$ 37.41
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(18,012)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 9.02
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	(417,916)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$ 53.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	3,707,337
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 35.90
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	3,597,026
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 36.72
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,723,405	4,159,333

Share-Based Incentive Plan (Non

Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details) - Restricted stock awards	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of restricted stock awards, nonvested beginning of period \| shares	31,096,783
Weighted average grant-date fair value per share, nonvested beginning of period \| $ / shares	$ 11.20
Number of restricted stock awards, granted \| shares	13,326,359
Weighted average grant-date fair value per share, granted \| $ / shares	$ 12.38
Number of restricted stock awards, released \| shares	(10,336,912)
Weighted average grant-date fair value per share, released \| $ / shares	$ 11.92
Number of restricted stock awards, forfeited \| shares	(1,305,912)
Weighted average grant-date fair value per share, forfeited \| $ / shares	$ 11
Number of restricted stock awards, nonvested end of period \| shares	32,780,318
Weighted average grant-date fair value per share, nonvested end of period \| $ / shares	$ 11.46

Pension and Other Postretiremen

Pension and Other Postretirement Benefit (Narrative) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plans, estimated benefit payments, in current fiscal year	$ 114.4
Estimated employer contributions in current year	$ 61.3

Pensions and Other Postretire_3

Pensions and Other Postretirement Benefits (Net Periodic Benefit Costs) (Details) - Pension and other postretirement benefits - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 7.9	$ 7.1
Interest cost	16.6	18.3
Expected return on plan assets	(16.9)	(16.4)
Amortization of prior service costs	0.5	0
Recognized net actuarial gains	(4.3)	(5)
Net periodic benefit cost	3.8	$ 4
Defined Benefit Plan Items \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Defined Benefit Plan Disclosure [Line Items]
Amortization of prior service costs	$ 0.5

Balance Sheet Components (Cash,

Balance Sheet Components (Cash, cash equivalents, and restricted cash) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 1,014.6	$ 991.9	$ 506.6
Restricted cash	1.3	1.7	4.1
Cash, cash equivalents and restricted cash	$ 1,015.9	$ 993.6	$ 510.7	$ 1,262.5

Balance Sheet Components (Inven

Balance Sheet Components (Inventories) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Balance Sheet Components [Abstract]
Raw materials	$ 686.7	$ 731.7
Work in process	1,097.5	602.1
Finished goods	2,039	2,135.9
Inventories	$ 3,823.2	$ 3,469.7

Balance Sheet Components (Prepa

Balance Sheet Components (Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Prepaid expenses	$ 178.9	$ 155.9
Fair value of financial instruments	73.3	106.2
Equity securities	52.1	49.3
Other current assets	249.5	271
Prepaid expenses and other current assets	1,933.3	2,028.1
Deferred Charges, Tax On Intercompany Profit	701.8	747.3
Income Taxes Receivable	310.7	340.2
Other Current Assets \| Biocon Biologics
Property, Plant and Equipment [Line Items]
Disposal Group, Including Discontinued Operation, Deferred Consideration Due	328.3	321.2
Available-for-sale fixed income investments
Property, Plant and Equipment [Line Items]
Available-for-sale securities	$ 38.7	$ 37

Balance Sheet Components (Prope

Balance Sheet Components (Property, Plant and Equipment) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 4,705.7	$ 4,770.3
Accumulated depreciation	1,997.5	2,010.7
Property, plant and equipment, net	2,708.2	2,759.6
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,745.8	2,774.5
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,438.8	1,444.4
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	406.5	431.2
Land and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 114.6	$ 120.2

Balance Sheet Components (Other

Balance Sheet Components (Other Assets) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Other Assets, Noncurrent [Abstract]
Operating lease right-of-use assets	$ 242.1	$ 245.6
Other long-term assets	800.6	821.1
Other assets	2,231.6	2,208.7
Convertible Preferred Stock
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Equity Securities, FV-NI, Cost	1,023.2	976.3
Private Equity Securities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Equity Securities, FV-NI, Cost	$ 165.7	$ 165.7

Balance Sheet Components (Trade

Balance Sheet Components (Trade Accounts Payable) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Accounts Payable, Current [Abstract]
Trade accounts payable	$ 1,584	$ 1,381.4
Other payables	612.9	556.8
Accounts payable	$ 2,196.9	$ 1,938.2

Balance Sheet Components (Oth_2

Balance Sheet Components (Other Current Liabilities) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Schedule of other current liabilities [Line Items]
Other receivables	$ 842	$ 876.6
Legal and professional accruals, including litigation accruals	321.6	244
Payroll and employee benefit liabilities	598.2	844.5
Contingent consideration (1)	569.9	215.1
Restructuring Reserve, Current	29.9	36.4
Accrued interest	204.7	66.8
Other Liabilities, Current	3,281.7	3,393.9
Fair value of financial instruments	70.1	124.6
Operating lease liability	91.8	83
Other	851.4	922.2
Liabilities held for sale	234.8	275.1
Other Current Liabilities [Member]
Schedule of other current liabilities [Line Items]
Contingent consideration (1)	105.2	76.1
Variable Consideration
Schedule of other current liabilities [Line Items]
Other receivables	$ 1,008.8	$ 996.3

Balance Sheet Components (Oth_3

Balance Sheet Components (Other Long-term Obligations) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Schedule of Other Noncurrent Liabilities [Line Items]
Employee benefit liabilities	$ 495.1	$ 504.3
Contingent consideration (1)	569.9	215.1
Tax related items, including contingencies	406.3	399.3
Operating Lease, Liability, Noncurrent	156.2	165.4
Restructuring Reserve, Noncurrent	57.9	59.2
Other	244.9	249.7
Other long-term obligations	1,825.1	1,516.9
Biocon Biologics
Schedule of Other Noncurrent Liabilities [Line Items]
Contingent consideration (1)	30	15.8
Other long-term obligations
Schedule of Other Noncurrent Liabilities [Line Items]
Contingent consideration (1)	$ 464.7	$ 139

Balance Sheet Components - Asse

Balance Sheet Components - Assets and Liabilities Held For Sale (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Liabilities held for sale	$ 234.8	$ 275.1

Earnings (Loss) per Ordinary _3

Earnings (Loss) per Ordinary Share (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended		14 Months Ended
	Mar. 15, 2024	Mar. 17, 2023	Mar. 31, 2024	Mar. 31, 2023	Feb. 28, 2024	Feb. 28, 2022
Earnings Per Share [Abstract]
Diluted (in USD per share)			$ 0.09	$ 0.19
Anti-dilutive stock options or restricted stock awards excluded from computation of earnings per share			7,900,000	13,900,000
Dividends paid (in dollars per share)		$ 0.12
Share repurchase program, authorized amount					$ 2,000	$ 1,000
Treasury Stock, Shares, Acquired			19,200,000	21,200,000
Payments for Repurchase of Common Stock			$ 250	$ 250
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Share repurchase program, authorized amount					2,000	$ 1,000
Stock Repurchased During Period, Value					$ 500
Idorsia Pharmaceuticals Ltd.
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Business Combination, Price of Acquisition, Expected	$ 350

Earnings (Loss) per Ordinary _4

Earnings (Loss) per Ordinary Share (Basic and Diluted Earnings Per Ordinary Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Earnings Per Share [Abstract]
Net earnings attributable to Viatris Inc. common shareholders	$ 113.9	$ 224.7
Weighted average shares outstanding	1,195.2	1,202.5
Basic earnings per share attributable to Viatris Inc. shareholders	$ 0.10	$ 0.19
Weighted average number diluted shares outstanding adjustment, stock-based awards and warrants	14.3	3.1
Total dilutive shares outstanding	1,209.5	1,205.6
Diluted earnings (loss) per ordinary share	$ 0.09	$ 0.19

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
In-process research and development	$ 994.1		$ 319.4
Contingent consideration (1)	569.9		215.1
Business Combination Contingent Consideration Liability Payments	(10.9)
Intangible asset disposal & impairment charges	0	$ 32
Goodwill	9,693.5		9,867.1
Emerging Markets Segment
Finite-Lived Intangible Assets [Line Items]
Goodwill	1,173.7		1,181.2
Japan, Australia and New Zealand Segment
Finite-Lived Intangible Assets [Line Items]
Goodwill	621.1		645.7
Greater China
Finite-Lived Intangible Assets [Line Items]
Goodwill	925.3		932.8
Other Current Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Contingent consideration (1)	105.2		$ 76.1
Business Combination Contingent Consideration Liability Payments	(10.9)
Reconciling items:
Finite-Lived Intangible Assets [Line Items]
Intangible asset disposal & impairment charges	$ 0	$ 32

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Changes in Carrying Amount of Goodwill) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Goodwill [Roll Forward]
Goodwill, net, beginning balance	$ 9,867.1
Acquisitions	19.5
Foreign currency translation	(193.1)
Goodwill	9,693.5	$ 9,867.1
Goodwill, Impaired, Accumulated Impairment Loss		(124)
Developed Markets Segment
Goodwill [Roll Forward]
Goodwill, net, beginning balance	7,107.4
Acquisitions	19.5
Foreign currency translation	(153.5)
Goodwill	6,973.4	7,107.4
Goodwill, Impaired, Accumulated Impairment Loss	(929)	(929)
Greater China
Goodwill [Roll Forward]
Goodwill, net, beginning balance	932.8
Acquisitions	0
Foreign currency translation	(7.5)
Goodwill	925.3	932.8
Japan, Australia and New Zealand Segment
Goodwill [Roll Forward]
Goodwill, net, beginning balance	645.7
Acquisitions	0
Foreign currency translation	(24.6)
Goodwill	621.1	645.7
Goodwill, Impaired, Accumulated Impairment Loss	(30)	(30)
Emerging Markets Segment
Goodwill [Roll Forward]
Goodwill, net, beginning balance	1,181.2
Acquisitions	0
Foreign currency translation	(7.5)
Goodwill	1,173.7	$ 1,181.2
Goodwill, Impaired, Accumulated Impairment Loss	$ (124)

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Components of Intangible Assets) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2023
Intangible Assets by Major Class [Line Items]
Intangible asset disposal & impairment charges	$ 0	$ 32
Finite-lived intangible assets, original cost	33,830.4			$ 34,178.1
Finite-lived intangible assets, accumulated amortization	15,690.8			15,316.4
Finite-lived intangible assets, net book value	18,139.6			18,861.7
In-process research and development	994.1			319.4
Intangible assets, gross, excluding goodwill	34,824.5			34,497.5
Intangible assets, net book value, excluding goodwill	$ 19,133.7			$ 19,181.1
Patents and technologies
Intangible Assets by Major Class [Line Items]
Finite-lived intangible assets, estimated useful life, in years	13 years			13 years
Licensing Agreements
Intangible Assets by Major Class [Line Items]
Write down of intangible assets		$ 32	$ 172.9

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets (Amortization Expense) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible asset amortization expense	$ 601	$ 603.3
Intangible asset disposal & impairment charges	0	32
Total intangible asset amortization expense (including disposal & impairment charges)	$ 601	$ 635.3

Goodwill and Intangibles Assets

Goodwill and Intangibles Assets (Expected Amortization Expense) (Details) $ in Millions	Mar. 31, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 1,750
2025	2,255
2026	2,205
2027	2,006
2028	$ 1,769

Financial Instruments and Ris_3

Financial Instruments and Risk Management (Narrative) (Details) € in Millions, ¥ in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)	May 09, 2024 EUR (€)	Mar. 31, 2024 EUR (€)	Mar. 31, 2024 JPY (¥)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2023 JPY (¥)	Oct. 31, 2023 EUR (€)
Derivative [Line Items]
Pre-tax net losses on cash flow hedges to be reclassified from AOCE into earnings in next twelve months \| $	$ 3
Contingent consideration (1) \| $	569.9				$ 215.1
Interest rate swaps \| Subsequent Event
Derivative [Line Items]
Derivative, Notional Amount		€ 500
Respiratory delivery platform
Derivative [Line Items]
Contingent consideration (1) \| $	173.2				177.6
Biocon Biologics
Derivative [Line Items]
Contingent consideration (1) \| $	30				15.8
Idorsia Pharmaceuticals Ltd.
Derivative [Line Items]
Contingent consideration (1) \| $	345
Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative			€ 5,600	¥ 40,000		€ 5,600	¥ 40,000
Long-term debt			5,600	40,000
Other Current Liabilities [Member]
Derivative [Line Items]
Contingent consideration (1) \| $	105.2				76.1
2024 Euro Senior Notes \| Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative			1,000			1,000
Long-term debt			1,000
2028 Euro Senior Notes \| Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative			750			750
Long-term debt			750
2020 Euro Senior Notes
Derivative [Line Items]
Long-term debt \| $	$ 264.3				$ 283.6
2.125% Euro Senior Notes due 2025 \| Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative			500			500
Long-term debt			500
2024 Euro Senior Notes, 1.023% \| Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative			750			750
Long-term debt			750
2027 Euro Senior Notes \| Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative			850			850
Long-term debt			850
2032 Euro Senior Notes \| Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative			1,250			1,250
Long-term debt			1,250
YEN Term Loan \| Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative \| ¥				40,000			¥ 40,000
Long-term debt \| ¥				40,000
2020 Floating Rate Euro Notes \| Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative			500			€ 500
Long-term debt			€ 500
Interest rate swaps \| Net Investment Hedging
Derivative [Line Items]
Derivative, Notional Amount \| ¥				¥ 14,600
Currency Swap \| Net Investment Hedging
Derivative [Line Items]
Derivative, Notional Amount								€ 500
Measurement Input, Discount Rate \| Contingent consideration \| Minimum
Derivative [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.085		0.085	0.085	0.064	0.064	0.064
Measurement Input, Discount Rate \| Contingent consideration \| Maximum
Derivative [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input					0.080	0.080	0.080

Financial Instruments and Ris_4

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Balance Sheets Fair Value of Derivative Instruments Derivatives Designated As Hedging Instruments) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 73.3	$ 106.2
Fair value of financial instruments	70.1	124.6
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	35.9	17.5
Fair value of financial instruments	10	35.8
Designated as Hedging Instrument \| Prepaid expenses and other current assets \| Foreign exchange forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	35.9	17.5
Designated as Hedging Instrument \| Other Current Liabilities [Member] \| Foreign exchange forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	10	35.8
Not Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	37.4	88.7
Fair value of financial instruments	60.1	88.8
Not Designated as Hedging Instruments \| Prepaid expenses and other current assets \| Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	37.4	88.7
Not Designated as Hedging Instruments \| Other Current Liabilities [Member] \| Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 60.1	$ 88.8

Financial Instruments and Ris_5

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Not Designated As Hedging Instrument) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 73.3	$ 106.2
Fair value of financial instruments	70.1	124.6
Not Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	37.4	88.7
Fair value of financial instruments	60.1	88.8
Not Designated as Hedging Instruments \| Prepaid expenses and other current assets \| Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	37.4	88.7
Not Designated as Hedging Instruments \| Other current liabilities \| Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 60.1	$ 88.8

Financial Instruments and Ris_6

Financial Instruments and Risk Management (Effect Of Derivative Instruments on the Condensed Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	$ 156.2	$ (41.7)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	5	7.7
Not Designated as Hedging Instruments
Derivative Instruments, Gain (Loss) [Line Items]
Net unrecognized gain on derivatives in cash flow hedging relationships	(21.6)	44.6
Foreign currency forward contracts \| Other expense \| Not Designated as Hedging Instruments
Derivative Instruments, Gain (Loss) [Line Items]
Net unrecognized gain on derivatives in cash flow hedging relationships	(22.8)	44.6
Cash Flow Hedging \| Foreign currency forward contracts \| Sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	24.8	11.1
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	6.6	8.9
Cash Flow Hedging \| Interest rate swaps \| Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	(1.2)	(0.9)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	(1.6)	(1.2)
Net Investment Hedging \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	10.7	0
Net Investment Hedging \| Foreign currency forward contracts \| Gains and Losses on Derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	117	(51.9)
Net Investment Hedging \| Interest rate swaps \| Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	4.9	0
Net unrecognized gain on derivatives in cash flow hedging relationships	$ 1.2	$ 0

Financial Instruments and Ris_7

Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	$ 52.1	$ 49.3
Fair value of financial instruments	73.3	106.2
Available-for-sale fixed income investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	38.7	37
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	500.3	651.4
Equity securities	52.1	49.3
Total assets at recurring fair value measurement	552.4	700.7
Level 1 \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	500.3	651.4
Level 1 \| Exchange traded funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	51.9	49.1
Level 1 \| Marketable securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0.2	0.2
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at recurring fair value measurement	112	143.2
Financial and Nonfinancial Liabilities, Fair Value Disclosure	70.1	124.6
Level 2 \| Foreign currency forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative assets	73.3	106.2
Foreign exchange derivative liabilities	70.1	124.6
Level 2 \| Available-for-sale fixed income investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	38.7	37
Level 2 \| Corporate Bond Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	14.4	15.9
Level 2 \| U.S. Treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	14.2	11.2
Level 2 \| Agency mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	3.2	4.6
Level 2 \| Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	4.9	5.1
Level 2 \| Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	2	0.2
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at recurring fair value measurement		976.3	$ 1,023.2
Financial and Nonfinancial Liabilities, Fair Value Disclosure	569.9	215.1
Level 3 \| Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other Liabilities, Fair Value Disclosure	569.9
Level 3 \| Convertible Preferred Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities, FV-NI	1,023.2	976.3
Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial instruments	$ 35.9	$ 17.5

Financial Instruments and Ris_8

Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	$ 215.1
Acquisition	345
Payments	10.9
Reclassifications	0
Accretion expense	15.9
Fair value loss	4.8
Balance at end of period	569.9
Biocon Biologics
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	15.8
Balance at end of period	30
Other Current Liabilities [Member]
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	76.1
Acquisition	0
Payments	10.9
Reclassifications	40
Accretion expense	0
Fair value loss	0
Balance at end of period	105.2
Other long-term obligations
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	139
Acquisition	345
Payments	0
Reclassifications	(40)
Accretion expense	15.9
Fair value loss	4.8
Balance at end of period	$ 464.7

Debt (Receivables, Securitizati

Debt (Receivables, Securitization Facility and Commercial Paper) (Details) $ in Millions	Mar. 31, 2024 USD ($)
Note Securitization Facility
Short-term Debt [Line Items]
Accounts receivable securitization facility maximum borrowing capacity	$ 200
Receivables Facility \| Revolving Credit Facility
Short-term Debt [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 400

Debt (Summary of Long-Term Debt

Debt (Summary of Long-Term Debt) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Current portion of long-term debt	$ 1,889.7	$ 1,934.7
Unamortized debt issuance expense	(28.4)	(29.5)
Long-term debt	16,072.5	16,188.1
Other Current Portion of Long-term Debt
Debt Instrument [Line Items]
Current portion of long-term debt	0.6	0.4
2020 Euro Senior Notes
Debt Instrument [Line Items]
Long-term debt	264.3	283.6
Other
Debt Instrument [Line Items]
Long-term debt	$ 2.4	2.4
2024 Euro Senior Notes, 1.023%
Debt Instrument [Line Items]
Stated percentage rate	1.023%
2027 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	1.362%
2027 Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	2.30%
Senior Notes \| 2024 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	2.25%
Long-term debt	$ 1,078.7	1,103.5
Senior Notes \| 2.125% Euro Senior Notes due 2025
Debt Instrument [Line Items]
Stated percentage rate	2.125%
Long-term debt	$ 539.3	551.7
Senior Notes \| 2026 Senior Notes (3.950% coupon)
Debt Instrument [Line Items]
Stated percentage rate	3.95%
Long-term debt	$ 2,245.6	2,245.1
Senior Notes \| 2028 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	3.125%
Long-term debt	$ 805.7	824.1
Senior Notes \| SeniorNotesTwoThousandTwentyEight [Member]
Debt Instrument [Line Items]
Stated percentage rate	4.55%
Senior Notes \| 2028 Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	$ 749.1	749.1
Senior Notes \| 2043 Senior Notes (5.400% coupon)
Debt Instrument [Line Items]
Stated percentage rate	5.40%
Long-term debt	$ 497.5	497.5
Senior Notes \| 2046 Senior Notes (5.250% coupon)
Debt Instrument [Line Items]
Stated percentage rate	5.25%
Long-term debt	$ 999.9	999.9
Senior Notes \| 2048 Senior Notes (5.200%)
Debt Instrument [Line Items]
Stated percentage rate	5.20%
Senior Notes \| 2048 Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	$ 747.8	747.8
Senior Notes \| 2024 Euro Senior Notes, 1.023%
Debt Instrument [Line Items]
Long-term debt	$ 810.9	831.5
Senior Notes \| 2025 Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	1.65%
Long-term debt	$ 754.8	755.7
Senior Notes \| 2027 Euro Senior Notes
Debt Instrument [Line Items]
Long-term debt	943.3	967.2
Senior Notes \| 2027 Senior Notes
Debt Instrument [Line Items]
Long-term debt	$ 768.4	769.8
Senior Notes \| 2030 Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	2.70%
Long-term debt	$ 1,503	1,505
Senior Notes \| 2032 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	1.908%
Long-term debt	$ 1,442.4	1,478.4
Senior Notes \| 2040 Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	3.85%
Long-term debt	$ 1,642.3	1,644
Senior Notes \| 2050 Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	4%
Long-term debt	$ 2,195.1	2,196.3
Current Portion of Long-Term Debt
Debt Instrument [Line Items]
Unamortized debt issuance expense	$ (0.5)	$ (0.7)

Debt (2016 and 2018 Revolving F

Debt (2016 and 2018 Revolving Facility and 2016 Term Facility) (Narrative) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Current portion of long-term debt	$ 1,889.7	$ 1,934.7

Debt (Fair Value) (Narrative) (

Debt (Fair Value) (Narrative) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Senior Notes
Debt Instrument [Line Items]
Fair value of long-term debt	$ 15,090	$ 15,250

Debt (Minimum Repayments on Out

Debt (Minimum Repayments on Outstanding Borrowings) (Details) $ in Millions	Dec. 31, 2023 USD ($)
Debt Disclosure [Abstract]
2024	$ 1,888
2025	1,289
2026	2,514
2027	1,667
2028	1,559
Thereafter	8,549
Total	$ 17,466

Comprehensive Earnings (Accumul

Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision	$ 90.7	$ 98
Net unrealized loss on available-for-sale fixed income securities, net of tax	(1.4)		$ (1.2)
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax	(266.4)		271.4
Foreign currency translation adjustment	(3,589.2)		(3,246.7)
Accumulated other comprehensive loss	(2,941)		(2,747.4)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	6.2	(1.3)
Sales Revenue, Goods, Net	3,653.5	3,719.1
Interest expense	138.4	147
Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gain (loss) on derivatives	28.7
Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulate Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Net Investment Hedges, Effect Net of Taxx	369.6		237.1
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision		(12.5)
Accumulated other comprehensive loss		(2,764.6)		$ (2,761.2)
Other comprehensive earnings (loss) before reclassifications, before tax	(142.4)	(3.2)
Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision		1.1
Net unrecognized gain (loss) on derivatives in cash flow hedging relationships, net of tax		(16.8)		(18.5)
Other comprehensive earnings (loss) before reclassifications, before tax		10.5
Gains and Losses on Derivatives \| Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision	7.1
Net unrecognized gain (loss) on derivatives in cash flow hedging relationships, net of tax			$ (8)
Other comprehensive earnings (loss) before reclassifications, before tax	33.7
Gains and Losses on Derivatives \| Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision	36.6	(14.3)
Net unrecognized gain (loss) on derivatives in cash flow hedging relationships, net of tax		325.1		377
Other comprehensive earnings (loss) before reclassifications, before tax		(66.2)
Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision		0.2
Net unrealized loss on available-for-sale fixed income securities, net of tax		(1.6)		(2.3)
Other comprehensive earnings (loss) before reclassifications, before tax		0.9
Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision		(0.5)
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax		269.3		268.5
Other comprehensive earnings (loss) before reclassifications, before tax	(2.4)	6.3
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision		0
Foreign currency translation adjustment		(3,340.6)		$ (3,385.9)
Other comprehensive earnings (loss) before reclassifications, before tax	(342.5)
Reclassification out of Accumulated Other Comprehensive Income [Member] \| AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision	42.4
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax	(0.5)
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax	4.3	5
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gain (loss) on derivatives		2.8
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision	(0.1)
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision	(1.2)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax		(1.3)
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision	0
Other Comprehensive Income (Loss), before Tax		45.3
Mylan N.V. \| Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gain (loss) on derivatives	169.1	(66.2)
Foreign currency forward contracts \| Gains and Losses on Derivatives \| Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales Revenue, Goods, Net	(6.6)
Foreign currency forward contracts \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales Revenue, Goods, Net	(6.6)	(8.9)
Foreign currency forward contracts \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales Revenue, Goods, Net	(6.6)	(8.9)
Interest rate swaps \| Gains and Losses on Derivatives \| Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.6
Interest rate swaps \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.6	1.2
Interest rate swaps \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.6	1.2
Pension and other postretirement benefits
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax	(0.5)	0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement	4.3	$ 5
Pension and other postretirement benefits \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax	$ (0.5)

Comprehensive Earnings (Compone

Comprehensive Earnings (Components Of Other Comprehensive Loss) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrealized gain (loss) on marketable securities, net of tax, beginning of period	$ (1.2)
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax	(266.4)		$ 271.4
Foreign currency translation adjustment, beginning of period	(3,246.7)
Accumulated other comprehensive loss, net of tax, beginning of period	(2,747.4)
Net sales	3,653.5	$ 3,719.1
Interest expense	138.4	147
Change in unrecognized gain and prior service cost related to defined benefit plans	(6.2)	1.3
Income tax expense	90.7	98
Net unrealized gain (loss) on marketable securities, net of tax, end of period	(1.4)
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, end of period	(266.4)
Foreign currency translation adjustment, end of period	(3,589.2)
Accumulated other comprehensive loss, net of tax, end of period	(2,941)
Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period		(18.5)
Other comprehensive earnings (loss) before reclassifications, before tax		10.5
Income tax expense		1.1
Net unrecognized gains (losses) on derivatives, net of tax, end of period		(16.8)
Gains and Losses on Derivatives \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax		2.8
Gains and Losses on Derivatives \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Foreign currency forward contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(6.6)	(8.9)
Gains and Losses on Derivatives \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.6	1.2
Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrealized gain (loss) on marketable securities, net of tax, beginning of period		(2.3)
Other comprehensive earnings (loss) before reclassifications, before tax		0.9
Income tax expense		0.2
Net unrealized gain (loss) on marketable securities, net of tax, end of period		(1.6)
Gains and Losses on Marketable Securities \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax expense	(0.1)
Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax		269.3		$ 268.5
Other comprehensive earnings (loss) before reclassifications, before tax	(2.4)	6.3
Income tax expense		(0.5)
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, end of period		269.3
Defined Benefit Plan Items \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Change in unrecognized gain and prior service cost related to defined benefit plans		1.3
Income tax expense	(1.2)
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation adjustment, beginning of period		(3,385.9)
Other comprehensive earnings (loss) before reclassifications, before tax	(342.5)
Income tax expense		0
Foreign currency translation adjustment, end of period		(3,340.6)
Foreign Currency Translation Adjustment \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive Income (Loss), before Tax		45.3
Income tax expense	0
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net of tax, beginning of period		(2,761.2)
Other comprehensive earnings (loss) before reclassifications, before tax	(142.4)	(3.2)
Income tax expense		(12.5)
Accumulated other comprehensive loss, net of tax, end of period		(2,764.6)
AOCI Attributable to Parent [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs	0.5
Other comprehensive earnings (loss), reclassification adjustment from AOCE, pension and other postretirement benefit plans, for net gain (loss), before tax	(4.3)	(5)
Income tax expense	42.4
AOCI Attributable to Parent [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Foreign currency forward contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(6.6)	(8.9)
AOCI Attributable to Parent [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.6	1.2
Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax	28.7
Cash Flow Hedging \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period	(8)
Other comprehensive earnings (loss) before reclassifications, before tax	33.7
Income tax expense	7.1
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax	13.6
Cash Flow Hedging \| Gains and Losses on Derivatives \| Foreign currency forward contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(6.6)
Cash Flow Hedging \| Gains and Losses on Derivatives \| Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.6
Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulate Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Net Investment Hedges, Effect Net of Taxx	369.6		$ 237.1
Net Investment Hedging \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period		377
Other comprehensive earnings (loss) before reclassifications, before tax		(66.2)
Income tax expense	36.6	(14.3)
Net unrecognized gains (losses) on derivatives, net of tax, end of period		325.1
Mylan N.V. \| Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax	169.1	(66.2)
Pension and other postretirement benefits
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs	0.5	0
Recognized net actuarial gains	(4.3)	$ (5)
Pension and other postretirement benefits \| Defined Benefit Plan Items \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs	$ 0.5

Segment Information (Reconcilia

Segment Information (Reconciliation Of Segment Information To Total Consolidated Information) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	$ 3,653.5	$ 3,719.1
Revenues	3,663.4	3,729.1
Amortization of Intangible Assets	(601)	(603.3)
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	0	(32)
Research and development	(199.7)	(182.9)
Litigation settlements and other contingencies, net	(76.8)	(0.6)
Earnings from operations	203.9	399.8
Other Research and Development Expense	(6.1)	0
Operating Segment
Segment Reporting Information [Line Items]
Earnings from operations	1,646.4	1,776.5
Reconciling items:
Segment Reporting Information [Line Items]
Amortization of Intangible Assets	(601)	(603.3)
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	0	(32)
Research and development	(199.7)	(182.9)
Litigation settlements and other contingencies, net	(76.8)	(0.6)
Other One-Time Nonoperating Expense	(202.3)	(178.5)
Corporate / Other
Segment Reporting Information [Line Items]
Corporate costs	356.6	379.4
Developed Markets Segment \| Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	2,165.4	2,170.4
Earnings from operations	913.3	938.7
Greater China \| Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	543.9	564.6
Earnings from operations	366.3	394.3
Japan, Australia and New Zealand Segment \| Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	317.8	342.2
Earnings from operations	87.3	130.5
Emerging Markets Segment \| Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	626.4	641.9
Earnings from operations	$ 279.5	$ 313

Collaboration and Licensing A_2

Collaboration and Licensing Agreements (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Jun. 30, 2023	Dec. 31, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Prepaid expenses and other current assets	$ 1,933.3		$ 2,028.1
Variable Interest Entity, Not Primary Beneficiary \| Mapi Pharma Ltd.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Variable Interest Entity, Maximum Milestone Payments	90
Variable Interest Entity, Financial or Other Support, Amount		$ 30
Equity Securities, FV-NI, Unrealized Gain (Loss)	45.6
Other Assets	132.1
Gain (Loss) on Investments	62.1
Prepaid expenses and other current assets	52.5
Collaborative Arrangement \| Mapi Pharma Ltd.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments to Acquire in Process Research and Development	75
Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments	409
Maximum \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments	$ 18

Income Taxes Income Taxes Discl

Income Taxes Income Taxes Disclosure (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2020
Income Tax Contingency [Line Items]
Income tax expense		$ 90.7	$ 98
Reserve for Uncertain Tax Positions, Including Interest And Penalties		281.8		$ 287.1
Foreign Tax Authority \| Australian Taxation Office
Income Tax Contingency [Line Items]
Income Tax Examination, Partial Payment Of Income Tax Expense		$ 5.2		$ 56
Foreign Tax Authority \| Ministry of Finance, India
Income Tax Contingency [Line Items]
Income tax expense	$ 22.3
Foreign Tax Authority \| Swedish Tax Authorities (STA)
Income Tax Contingency [Line Items]
Amount of income tax, including interest and penalties under appeal					$ 19

Litigation (Lorazepam and Clora

Litigation (Lorazepam and Clorazepate) (Narrative) (Details) $ in Millions	Mar. 31, 2024 USD ($)
Opiod Civil Litigation
Loss Contingencies [Line Items]
Loss Contingency Accrual	$ 150.7

Litigation (Pricing and Medicai

Litigation (Pricing and Medicaid Litigation) (Narrative) (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Loss Contingencies [Line Items]
Other current liabilities	$ 3,281.7	$ 3,393.9

Litigation (MDRP Classification

Litigation (MDRP Classification of EpiPen Auto-Injector and EpiPen Jr Auto-Injector) (Details) $ in Millions	Mar. 31, 2024 USD ($)
Other Current Liabilities [Member]
Loss Contingencies [Line Items]
Estimated litigation liability	$ 5.5

Litigation (Drug Pricing Matter

Litigation (Drug Pricing Matters) (Details) - Mar. 31, 2024	Total	state
Multi District Litigation [Member]
Loss Contingencies [Line Items]
Number of states	44	44
Anticompetitive Conduct with Generic Drugs [Member]
Loss Contingencies [Line Items]
Number of states	45
Amended Anticompetitive Conduct with Generic Drugs [Member]
Loss Contingencies [Line Items]
Number of states	40

Litigation (U.K. Competition an

Litigation (U.K. Competition and Markets Authority) (Narrative) (Details) € in Millions	Mar. 31, 2024 EUR (€)
Citalopram Litigation
Loss Contingencies [Line Items]
Estimated litigation liability	€ 12.2

Litigation (Product Liability)

Litigation (Product Liability) (Narrative) (Details) $ in Millions	Mar. 31, 2024 USD ($)
Product Liability
Loss Contingencies [Line Items]
Loss Contingency Accrual	$ 65.3

Litigation (Intellectual Proper

Litigation (Intellectual Property) (Narrative) (Details) - Intellectual Property $ in Millions	1 Months Ended		3 Months Ended
	Apr. 30, 2024 right	Mar. 31, 2024 right	Mar. 31, 2024 USD ($)
Loss Contingencies [Line Items]
Damages to be paid \| $			$ 5.1
Amitiza ® \| Subsequent Event
Loss Contingencies [Line Items]
Number Of Patents	3
Tyrvaya ®
Loss Contingencies [Line Items]
Number Of Patents		4

Litigation (Other Litigation) (

Litigation (Other Litigation) (Narrative) (Details) - Mar. 31, 2024 $ in Millions	USD ($)	Total	state
Loss Contingencies [Line Items]
Number of cases		1,000
Multi District Litigation [Member]
Loss Contingencies [Line Items]
Number of states		44	44
Amended Multi District Litigation
Loss Contingencies [Line Items]
Number of states		34
Anticompetitive Conduct with Generic Drugs [Member]
Loss Contingencies [Line Items]
Number of states		45
Amended Anticompetitive Conduct with Generic Drugs [Member]
Loss Contingencies [Line Items]
Number of states		40
Other Litigation
Loss Contingencies [Line Items]
Loss Contingency Accrual	$ 6.5